1
|
Codden RR, Sweeney C, Ofori-Atta BS, Herget KA, Wigren K, Edwards S, Carter ME, McCarty RD, Hashibe M, Doherty JA, Millar MM. Accuracy of patient race and ethnicity data in a central cancer registry. Cancer Causes Control 2024; 35:685-694. [PMID: 38019367 PMCID: PMC10960663 DOI: 10.1007/s10552-023-01827-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 11/02/2023] [Indexed: 11/30/2023]
Abstract
PURPOSE Race and Hispanic ethnicity data can be challenging for central cancer registries to collect. We evaluated the accuracy of the race and Hispanic ethnicity variables collected by the Utah Cancer Registry compared to self-report. METHODS Participants were 3,162 cancer survivors who completed questionnaires administered in 2015-2022 by the Utah Cancer Registry. Each survey included separate questions collecting race and Hispanic ethnicity, respectively. Registry-collected race and Hispanic ethnicity were compared to self-reported values for the same individuals. We calculated sensitivity and specificity for each race category and Hispanic ethnicity separately. RESULTS Survey participants included 323 (10.2%) survivors identifying as Hispanic, a lower proportion Hispanic than the 12.1% in the registry Hispanic variable (sensitivity 88.2%, specificity 96.5%). For race, 43 participants (1.4%) self-identified as American Indian or Alaska Native (AIAN), 32 (1.0%) as Asian, 23 (0.7%) as Black or African American, 16 (0.5%) Pacific Islander (PI), and 2994 (94.7%) as White. The registry race variable classified a smaller proportion of survivors as members of each of these race groups except White. Sensitivity for classification of race as AIAN was 9.3%, Asian 40.6%, Black 60.9%, PI 25.0%, and specificity for each of these groups was > 99%. Sensitivity and specificity for White were 98.8% and 47.4%. CONCLUSION Cancer registry race and Hispanic ethnicity data often did not match the individual's self-identification. Of particular concern is the high proportion of AIAN individuals whose race is misclassified. Continued attention should be directed to the accurate capture of race and ethnicity data by hospitals.
Collapse
Affiliation(s)
- Rachel R Codden
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
| | - Carol Sweeney
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| | - Blessing S Ofori-Atta
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | | | - Kacey Wigren
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
| | - Sandra Edwards
- Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA
| | | | - Rachel D McCarty
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Mia Hashibe
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
- Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Jennifer A Doherty
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Morgan M Millar
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
| |
Collapse
|
2
|
Kaddas HK, Millar MM, Herget KA, Carter ME, Ofori-Atta BS, Edwards SL, Codden RR, Sweeney C, Kirchhoff AC. Material financial hardship and insurance-related experiences among Utah's rural and urban cancer survivors. J Cancer Surviv 2024:10.1007/s11764-024-01546-x. [PMID: 38340250 DOI: 10.1007/s11764-024-01546-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Accepted: 01/28/2024] [Indexed: 02/12/2024]
Abstract
PURPOSE Describe material financial hardship (e.g., using savings, credit card debt), insurance, and access to care experienced by Utah cancer survivors; investigate urban-rural differences in financial hardship. METHODS Cancer survivors were surveyed from 2018 to 2021 about their experiences with financial hardship, access to healthcare, and job lock (insurance preventing employment changes). Weighed percentage responses, univariable and multivariable logistic regression models for these outcomes compared differences in survivors living in rural and urban areas based on Rural-Urban Commuting Area Codes. RESULTS The N = 1793 participants were predominantly Non-Hispanic White, female, and 65 or older at time of survey. More urban than rural survivors had a college degree (39.8% vs. 31.0%, p = 0.04). Overall, 35% of survivors experienced ≥ 1 financial hardship. In adjusted analyses, no differences were observed between urban and rural survivors for: material financial hardship, the overall amount of hardship reported, insurance status at survey, access to healthcare, or job lock. Hispanic rural survivors were less likely to report financial hardship than Hispanic urban survivors (odds ratio (OR) = 0.24, 95%CI = 0.08-0.73)). Rural survivors who received chemo/immune therapy as their only treatment were more likely to report at least one instance of financial hardship than urban survivors (OR = 2.72, 95%CI = 1.08-6.86). CONCLUSIONS The relationship between rurality and financial hardship among survivors may be most burdensome for patients whose treatments require travel or specialty medication access. IMPLICATIONS FOR CANCER SURVIVORS The impact of living rurally on financial difficulties after cancer diagnoses is complex. Features of rurality that may alter financial difficulty after a cancer diagnosis may vary geographically and instead of considering rurality as a stand-alone factor, these features should be investigated independently.
Collapse
Affiliation(s)
- Heydon K Kaddas
- Cancer Control and Population Sciences, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, Utah, 84112, USA.
| | - Morgan M Millar
- Cancer Control and Population Sciences, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, Utah, 84112, USA
- Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah, USA
| | | | | | | | - Sandra L Edwards
- Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA
| | - Rachel R Codden
- Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah, USA
| | - Carol Sweeney
- Cancer Control and Population Sciences, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, Utah, 84112, USA
- Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah, USA
| | - Anne C Kirchhoff
- Cancer Control and Population Sciences, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, Utah, 84112, USA
- Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA
| |
Collapse
|
3
|
Phillips R, Proudfoot J, Davicioni E, Spratt DE, Feng FY, Simko J, Den RB, Pollack A, Rosenthal SA, Sartor O, Sweeney C, Attard G, Patel SI, Hall WA, Efstathiou JA, Shah AB, Hoffman KE, Pugh S, Sandler HM, Tran PT. Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:S34-S35. [PMID: 37784480 DOI: 10.1016/j.ijrobp.2023.06.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Decipher is a prognostic genomic classifier (GC) validated in several prospective NRG Oncology Phase III trials. Herein, we validate the GC in pre-treatment biopsy samples for risk stratification in a cohort of high-risk men treated with definitive radiotherapy and androgen suppression with or without docetaxel chemotherapy. MATERIALS/METHODS As per a pre-specified and approved NCI analysis plan (Navigator #1061), we obtained available formalin-fixed paraffin-embedded tissue from biopsy specimens from the NRG biobank from patients enrolled on the NRG/RTOG 0521 randomized phase III trial. After central review, the highest-grade tumors were profiled on clinical-grade whole-transcriptome arrays (Veracyte, San Diego, CA) and GC scores were obtained. Pre-specified categorical GC scores, adjusted for archival tissue analysis, were used to define higher (>0.46) and lower (≤0.46) risk groups. The primary objective was to validate the independent prognostic ability of GC for metastasis-free survival (MFS) with Cox multivariable analyses (MVA). RESULTS Samples were obtained from 283 consented, evaluable patients with tissue (50% of trial) yielding 183 (65%) GC scores that passed quality metrics, 91 from control and 92 from the interventional arm. Median age was 66 years, median PSA was 19.3 ng/uL (IQR: 8.1-41.4), 81% had clinical stage ≥T2 and 80% had Gleason score ≥8 (47% ≥9). Median GC score was 0.55 (IQR: 0.38-0.78) and overall the arms were balanced for key covariates. With a median follow-up of 9.9 years (IQR: 9.3, 10.7), 67 MFS events including 34 distant metastases (DM) were observed. On MVA, only the GC (per 0.1 unit) was independently associated with MFS (HR 1.12, 95% CI 1.01-1.25) as well as DM (sHR 1.22, 95% CI 1.06-1.41), whereas the 4 pre-defined trial risk groups used for stratification (based on Gleason score, T-stage and PSA), randomization and patient age were not. For categorical GC, on MVA, higher-risk GC patients (65%) had worse DM (sHR 2.82, 95% CI 1.1-7.3) compared to those with lower GC. Cumulative incidence of DM at 10-years was 27% for higher GC vs 9% (95% CI 7-18%) for lower GC. No biomarker-by-treatment interaction with GC and the addition of docetaxel was detected. CONCLUSION In pre-treatment biopsy samples from a randomized Phase 3 trial cohort, GC demonstrated its ability to further risk stratify clinically high-risk men demonstrating an independent association of GC score with DM and MFS. High-risk prostate cancer is a heterogeneous disease state and GC can improve risk stratification to help personalize shared decision-making. NRG-GU009/PREDICT-RT (NCT04513717) aims to determine the optimal therapy based on GC score for high-risk prostate cancer.
Collapse
Affiliation(s)
- R Phillips
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | | | | | - D E Spratt
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
| | - F Y Feng
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA
| | | | - R B Den
- Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, PA
| | - A Pollack
- Department of Radiation Oncology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL
| | - S A Rosenthal
- Sutter Medical Group and Cancer Center, Sacramento, CA
| | - O Sartor
- Tulane University, New Orleans, LA
| | - C Sweeney
- South Australian Immunogenomics Cancer Institute, Adelaide, Australia
| | - G Attard
- The Institute of Cancer Research, London, United Kingdom
| | - S I Patel
- Division of Radiation Oncology, University of Alberta, Edmonton, AB, Canada
| | - W A Hall
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI
| | - J A Efstathiou
- Department of Radiation Oncology, Harvard School of Medicine, Boston, MA
| | - A B Shah
- York Cancer Center, York, PA, United States
| | - K E Hoffman
- Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Pugh
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA
| | - H M Sandler
- Cedars-Sinai Medical Center, Los Angeles, CA
| | - P T Tran
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| |
Collapse
|
4
|
Sutera P, Shetty A, Hakansson A, Van der Eecken K, Song Y, Liu Y, Fonteyne V, Verbeke S, Song D, Ross AE, Feng FY, Gillessen S, Attard G, James N, Lotan TL, Davicioni E, Sweeney C, Tran PT, Deek MP, Ost P. Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e261-e262. [PMID: 37785002 DOI: 10.1016/j.ijrobp.2023.06.1217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Metastatic castration-sensitive prostate cancer (mCSPC) is commonly partitioned into high- and low-volume subgroups which have demonstrated differential biology, prognosis, and response to therapy. Timing of metastasis has similarly demonstrated differences in clinical outcomes, however less is known about any potential underlying biologic differences between these disease states. Herein we aim to compare transcriptomic differences between synchronous and metachronous mCSPC and identify any differential responses to therapy. MATERIALS/METHODS We performed an international multi-institutional retrospective review of men with mCSPC who completed RNA expression profiling evaluation of their primary tumor. Patients were stratified according to disease timing (synchronous vs metachronous). The primary endpoint was to identify differences in transcriptomic profiles between disease time. Median genomic scores between groups were compared with Mann-Whitney U test. Secondary analyses included determining clinical and transcriptomic variables associated with overall survival (OS) from time of metastasis. Survival analysis was performed with the Kaplan-Meier Method and Multivariable Cox regression. RESULTS A total of 252 patients were included with a median follow-up of 39.6 months. Patients with synchronous disease experienced worse 5-yr OS (39% vs 79%, p<0.01) and demonstrated lower median Androgen Receptor Activity (AR-A) (11.78 vs 12.64, p<0.01) and Hallmark Androgen Response (HAR) (3.15 vs 3.32; p<0.01). Multivariable cox-regression identified only high-volume disease (HR = 4.97, 95% CI 2.71-9.10; p<0.01) and HAR score (HR = 0.51, 95% CI 0.28-0.88; p = 0.02 significantly associated with OS. Finally, patients with synchronous (HR = 0.47, 95% CI 0.30-0.72; <0.01) but not metachronous (HR = 1.37, 95% CI 0.50-3.92; p = 0.56) disease were found to have better OS with Androgen Receptor (AR) + non-AR combination therapy as compared to monotherapy (p value for interaction = 0.05). CONCLUSION We have demonstrated a potential biologic difference between metastatic timing of mCSPC. Specifically, for patients with low volume disease, those with metachronous low volume disease have a more hormone dependent transcriptional profile and exhibit a better prognosis than synchronous low volume disease.
Collapse
Affiliation(s)
- P Sutera
- Johns Hopkins University School of Medicine, Baltimore, MD
| | - A Shetty
- University of Maryland, Baltimore, MD
| | | | - K Van der Eecken
- Department of Pathology and Human Structure and Repair, University of Ghent, Ghent, Belgium
| | - Y Song
- University of Maryland, Baltimore, MD
| | - Y Liu
- Decipher/Veractye, San Francisco, CA
| | - V Fonteyne
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - S Verbeke
- Department of Pathology, Ghent University Hospital, Ghent, Ghent, Belgium
| | - D Song
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
| | | | - F Y Feng
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA
| | - S Gillessen
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
| | - G Attard
- The Institute of Cancer Research, London, United Kingdom
| | - N James
- The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom
| | - T L Lotan
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
| | | | - C Sweeney
- University of Adelaide, Adelaide, Australia
| | - P T Tran
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - M P Deek
- Rutgers Cancer Institute of New Jersey, Department of Radiation Oncology, New Brunswick, NJ
| | - P Ost
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| |
Collapse
|
5
|
Sutera P, Deek MP, Jing Y, Pryor DI, Huynh MA, Koontz BF, Mercier C, Ost P, Kiess AP, Conde-Moreno AJ, Stish BJ, Bosetti DG, Siva S, Berlin A, Kroeze S, Corcoran N, Trock B, Gillessen S, Tran PT, Sweeney C. Multi-Institutional Analysis of Metastasis Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e442-e443. [PMID: 37785433 DOI: 10.1016/j.ijrobp.2023.06.1620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Several prospective trials in oligometastatic castration sensitive prostate cancer (omCSPC) have shown metastasis-directed therapy (MDT) can delay time to progression and initiation of androgen deprivation therapy (ADT) compared to observation. However, the optimal integration of ADT with MDT remains unclear. Here we report a multi-national, multi-institutional retrospective cohort of omCSPC treated with MDT to characterize the long-term outcomes of patients treated with MDT alone or in combination with ADT. MATERIALS/METHODS Patients with a controlled primary site and omCSPC (defined as ≤ 5 lesions on conventional imaging) treated with MDT with or without concurrent ADT and with at least 36 months follow-up were retrospectively screened across 13 institutions. The primary endpoints included biochemical progression free survival (bPFS) and radiographic progression free survival (rPFS) calculated using Kaplan-Meier method and stratified by treatment group (MDT alone vs MDT + ADT). Multivariable Cox regression was performed adjusted for variables found to be prognostic on univariate analysis. RESULTS Among 414 patients screened, a total of 263 patients treated between 2003 and 2018 met inclusion criteria and included. Of these, 105 received MDT alone and 158 received MDT+ADT, with median follow-up of 49.5 and 54.5 months, respectively. The majority were metachronous (90%) and had bone lesions (60%). Median ADT duration was 21.3 months (IQR 12.0- 31.9). Patients who received ADT vs. no ADT had poorer prognostic features including 23% vs. 1% synchronous (p<0.001), and 55% vs 40% Gleason 8-10 (p = 0.012). ADT use was associated with a better 5-year bPFS 24% vs 11% (p<0.0001) and rPFS 41% vs 29% (p<0.001). On multivariable Cox regression adjusting for post-MDT PSA nadir and salvage therapy, ADT use maintained significance for both bPFS (HR 0.51 (0.36, 0.71), p<0.001) and rPFS (HR 0.67, 95% CI 0.46-0.96, p = 0.03). CONCLUSION Long-term outcomes with MDT alone suggest a small proportion of patients experience sustained disease control. The addition of ADT appears to improve rPFS, however prospective studies are needed in order to allow for personalization of care in patients with omCSPC.
Collapse
Affiliation(s)
- P Sutera
- Johns Hopkins University School of Medicine, Baltimore, MD
| | - M P Deek
- Rutgers Cancer Institute of New Jersey, Department of Radiation Oncology, New Brunswick, NJ
| | - Y Jing
- Johns Hopkins, Baltimore, MD
| | - D I Pryor
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - M A Huynh
- Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | | | - C Mercier
- Gasthuis Sisters, Antwerpen, Belgium
| | - P Ost
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - A P Kiess
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
| | | | - B J Stish
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - D G Bosetti
- Department of Radiation Oncology, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
| | - S Siva
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - A Berlin
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - S Kroeze
- University Hospital Zurich, Zurich, Switzerland
| | - N Corcoran
- University of Melbourne, Melbourne, Australia
| | - B Trock
- Brady Urological Institute at Johns Hopkins Medical Institution, Baltimore, MD
| | - S Gillessen
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
| | - P T Tran
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD
| | - C Sweeney
- University of Adelaide, Adelaide, Australia
| |
Collapse
|
6
|
Sutera PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, Chang J, Fonteyne V, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Rana Z, Hodges T, Hamid A, Roberts N, Song DY, Pienta K, Ross AE, Feng F, Joniau S, Spratt D, Gillessen S, Attard G, James ND, Lotan T, Davicioni E, Sweeney C, Tran PT, Deek MP, Ost P. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol 2023; 34:605-614. [PMID: 37164128 PMCID: PMC10330666 DOI: 10.1016/j.annonc.2023.04.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 04/26/2023] [Accepted: 04/27/2023] [Indexed: 05/12/2023] Open
Abstract
BACKGROUND Metastatic castration-sensitive prostate cancer (mCSPC) is commonly classified into high- and low-volume subgroups which have demonstrated differential biology, prognosis, and response to therapy. Timing of metastasis has similarly demonstrated differences in clinical outcomes; however, less is known about any underlying biologic differences between these disease states. Herein, we aim to compare transcriptomic differences between synchronous and metachronous mCSPC and identify any differential responses to therapy. PATIENTS AND METHODS We performed an international multi-institutional retrospective review of men with mCSPC who completed RNA expression profiling evaluation of their primary tumor. Patients were stratified according to disease timing (synchronous versus metachronous). The primary endpoint was to identify differences in transcriptomic profiles between disease timing. The median transcriptomic scores between groups were compared with the Mann-Whitney U test. Secondary analyses included determining clinical and transcriptomic variables associated with overall survival (OS) from the time of metastasis. Survival analysis was carried out with the Kaplan-Meier method and multivariable Cox regression. RESULTS A total of 252 patients were included with a median follow-up of 39.6 months. Patients with synchronous disease experienced worse 5-year OS (39% versus 79%; P < 0.01) and demonstrated lower median androgen receptor (AR) activity (11.78 versus 12.64; P < 0.01) and hallmark androgen response (HAR; 3.15 versus 3.32; P < 0.01). Multivariable Cox regression identified only high-volume disease [hazard ratio (HR) = 4.97, 95% confidence interval (CI) 2.71-9.10; P < 0.01] and HAR score (HR = 0.51, 95% CI 0.28-0.88; P = 0.02) significantly associated with OS. Finally, patients with synchronous (HR = 0.47, 95% CI 0.30-0.72; P < 0.01) but not metachronous (HR = 1.37, 95% CI 0.50-3.92; P = 0.56) disease were found to have better OS with AR and non-AR combination therapy as compared with monotherapy (P value for interaction = 0.05). CONCLUSIONS We have demonstrated a potential biologic difference between metastatic timing of mCSPC. Specifically, for patients with low-volume disease, those with metachronous low-volume disease have a more hormone-dependent transcriptional profile and exhibit a better prognosis than synchronous low-volume disease.
Collapse
Affiliation(s)
- P A Sutera
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, USA
| | - A C Shetty
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
| | | | - K Van der Eecken
- Department of Pathology, Ghent University Hospital, Ghent, Belgium
| | - Y Song
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
| | | | - J Chang
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
| | - V Fonteyne
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - A A Mendes
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA
| | - N Lumen
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - L Delrue
- Department of Radiology, Ghent University Hospital, Ghent, Belgium
| | - S Verbeke
- Department of Pathology, Ghent University Hospital, Ghent, Belgium
| | - K De Man
- Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium
| | - Z Rana
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
| | - T Hodges
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
| | - A Hamid
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - N Roberts
- Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, USA
| | - D Y Song
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, USA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA; James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, USA
| | - K Pienta
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA; James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, USA
| | - A E Ross
- Department of Urology, Northwestern University, Chicago, USA
| | - F Feng
- Department of Medicine, UCSF, San Francisco, USA; Department of Urology, UCSF, San Francisco, USA; Department of Radiation Oncology, UCSF, San Francisco, USA
| | - S Joniau
- Department of Urology, Catholic University Leuven, Leuven, Belgium
| | - D Spratt
- Department of Radiation Oncology, University Hospitals, Cleveland, USA
| | - S Gillessen
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
| | - G Attard
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK
| | - N D James
- The Royal Marsden Hospital NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK
| | - T Lotan
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA
| | | | - C Sweeney
- South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia
| | - P T Tran
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
| | - M P Deek
- Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
| | - P Ost
- Department of Radiation Oncology, Iridium Network, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
| |
Collapse
|
7
|
Millar MM, Herget KA, Ofori-Atta B, Codden RR, Edwards SL, Carter ME, Belnap B, Kirchhoff AC, Sweeney C. Cancer survivorship experiences in Utah: an evaluation assessing indicators of survivors' quality of life, health behaviors, and access to health services. Cancer Causes Control 2023; 34:337-347. [PMID: 36723708 PMCID: PMC10367944 DOI: 10.1007/s10552-023-01671-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 01/14/2023] [Indexed: 02/02/2023]
Abstract
PURPOSE The 2016-2020 Utah Comprehensive Cancer Prevention and Control Plan prioritized strategies to address cancer survivorship experiences. In this paper we present estimates for nine indicators evaluating these priorities, trends over time, and assess disparities in survivorship experiences across demographic subgroups. METHODS We surveyed a representative sample of Utah cancer survivors diagnosed between 2012 and 2019 with any reportable cancer diagnosis. We calculated weighted percentages and 95% confidence intervals (CI) for each indicator. We assessed change over time using a test for trend across survey years in a logistic regression model and used Rao-Scott F-adjusted chi-square tests to test the association between demographic characteristics and each survivorship indicator. RESULTS Most of the 1,793 respondents (93.5%) reported their pain was under control, 85.7% rated their overall health as good, very good, or excellent, but 46.5% experienced physical, mental, or emotional limitations. Only 1.7% of survivors aged 75 or older were current smokers, compared to 5.8% of 65-74-year-olds and 7.9% of survivors aged 55-74 (p < 0.006). No regular physical activity was reported by 20.6% and varied by survivor age and education level. The proportion who received a survivorship care plan increased from 34.6% in 2018 to 43.0% in 2021 (p = 0.025). However, survivors under age 55 were significantly less likely to receive a care plan than older survivors. CONCLUSION This representative survey of cancer survivors fills a gap in understanding of the cancer survivorship experience in Utah. Results can be used to evaluate and plan additional interventions to improve survivorship quality of life.
Collapse
Affiliation(s)
- Morgan M Millar
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA.
- Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
| | | | | | - Rachel R Codden
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
- Division of Epidemiology, University of Utah, Salt Lake City, UT, USA
| | - Sandra L Edwards
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
| | | | - Brad Belnap
- Utah Department of Health and Human Services, Utah Cancer Control Program, Salt Lake City, UT, USA
| | - Anne C Kirchhoff
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
- Department of Pediatrics, University of Utah, Salt Lake City, UT, USA
| | - Carol Sweeney
- Utah Cancer Registry, University of Utah, Salt Lake City, UT, USA
- Division of Epidemiology, University of Utah, Salt Lake City, UT, USA
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| |
Collapse
|
8
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
Affiliation(s)
- Fabio Girardi
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.,Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Melissa Matz
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | - Charles Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Hui You
- Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia
| | - Rafael Marcos Gragera
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Mikhail Y Valkov
- Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia
| | - Jean-Luc Bulliard
- Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.,Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
| | - Prithwish De
- Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada
| | - David Morrison
- Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK
| | - Miriam Wanner
- Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland
| | - David K O'Brian
- Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA
| | - Nathalie Saint-Jacques
- Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Michel P Coleman
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Acero MA, Adamson P, Aliaga L, Anfimov N, Antoshkin A, Arrieta-Diaz E, Asquith L, Aurisano A, Back A, Baird M, Balashov N, Baldi P, Bambah BA, Bashar S, Bays K, Bernstein R, Bhatnagar V, Bhattarai D, Bhuyan B, Bian J, Booth AC, Bowles R, Brahma B, Bromberg C, Buchanan N, Butkevich A, Calvez S, Carroll TJ, Catano-Mur E, Childress S, Chatla A, Chirco R, Choudhary BC, Christensen A, Coan TE, Colo M, Cremonesi L, Davies GS, Derwent PF, Ding P, Djurcic Z, Dolce M, Doyle D, Dueñas Tonguino D, Dukes EC, Ehrlich R, Elkins M, Ewart E, Feldman GJ, Filip P, Franc J, Frank MJ, Gallagher HR, Gandrajula R, Gao F, Giri A, Gomes RA, Goodman MC, Grichine V, Groh M, Group R, Guo B, Habig A, Hakl F, Hall A, Hartnell J, Hatcher R, Hausner H, He M, Heller K, Hewes V, Himmel A, Jargowsky B, Jarosz J, Jediny F, Johnson C, Judah M, Kakorin I, Kaplan DM, Kalitkina A, Keloth R, Klimov O, Koerner LW, Kolupaeva L, Kotelnikov S, Kralik R, Kullenberg C, Kubu M, Kumar A, Kuruppu CD, Kus V, Lackey T, Lang K, Lasorak P, Lesmeister J, Lin S, Lister A, Liu J, Lokajicek M, Lopez JMC, Mahji R, Magill S, Manrique Plata M, Mann WA, Manoharan MT, Marshak ML, Martinez-Casales M, Matveev V, Mayes B, Messier MD, Meyer H, Miao T, Mikola V, Miller WH, Mishra S, Mishra SR, Mislivec A, Mohanta R, Moren A, Morozova A, Mu W, Mualem L, Muether M, Mulder K, Naples D, Nath A, Nayak N, Nelleri S, Nelson JK, Nichol R, Niner E, Norman A, Norrick A, Nosek T, Oh H, Olshevskiy A, Olson T, Ott J, Pal A, Paley J, Panda L, Patterson RB, Pawloski G, Petrova O, Petti R, Phan DD, Plunkett RK, Pobedimov A, Porter JCC, Rafique A, Prais LR, Raj V, Rajaoalisoa M, Ramson B, Rebel B, Rojas P, Roy P, Ryabov V, Samoylov O, Sanchez MC, Sánchez Falero S, Shanahan P, Shukla S, Sheshukov A, Singh I, Singh P, Singh V, Smith E, Smolik J, Snopok P, Solomey N, Sousa A, Soustruznik K, Strait M, Suter L, Sutton A, Swain S, Sweeney C, Sztuc A, Talaga RL, Tapia Oregui B, Tas P, Temizel BN, Thakore T, Thayyullathil RB, Thomas J, Tiras E, Tripathi J, Trokan-Tenorio J, Torun Y, Urheim J, Vahle P, Vallari Z, Vasel J, Vrba T, Wallbank M, Warburton TK, Wetstein M, Whittington D, Wickremasinghe DA, Wieber T, Wolcott J, Wu W, Xiao Y, Yaeggy B, Yallappa Dombara A, Yankelevich A, Yonehara K, Yu S, Yu Y, Zadorozhnyy S, Zalesak J, Zhang Y, Zwaska R. Measurement of the ν_{e}-Nucleus Charged-Current Double-Differential Cross Section at ⟨E_{ν}⟩=2.4 GeV Using NOvA. Phys Rev Lett 2023; 130:051802. [PMID: 36800478 DOI: 10.1103/physrevlett.130.051802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 09/13/2022] [Accepted: 11/08/2022] [Indexed: 06/18/2023]
Abstract
The inclusive electron neutrino charged-current cross section is measured in the NOvA near detector using 8.02×10^{20} protons-on-target in the NuMI beam. The sample of GeV electron neutrino interactions is the largest analyzed to date and is limited by ≃17% systematic rather than the ≃7.4% statistical uncertainties. The double-differential cross section in final-state electron energy and angle is presented for the first time, together with the single-differential dependence on Q^{2} (squared four-momentum transfer) and energy, in the range 1 GeV≤E_{ν}<6 GeV. Detailed comparisons are made to the predictions of the GENIE, GiBUU, NEUT, and NuWro neutrino event generators. The data do not strongly favor a model over the others consistently across all three cross sections measured, though some models have especially good or poor agreement in the single differential cross section vs Q^{2}.
Collapse
Affiliation(s)
- M A Acero
- Universidad del Atlantico, Carrera 30 No. 8-49, Puerto Colombia, Atlantico, Colombia
| | - P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Aliaga
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Anfimov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - A Antoshkin
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - E Arrieta-Diaz
- Universidad del Magdalena, Carrera 32 No 22-08 Santa Marta, Colombia
| | - L Asquith
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A Back
- Indiana University, Bloomington, Indiana 47405, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - M Baird
- Indiana University, Bloomington, Indiana 47405, USA
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Balashov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - P Baldi
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - B A Bambah
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - S Bashar
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - K Bays
- California Institute of Technology, Pasadena, California 91125, USA
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - R Bernstein
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - V Bhatnagar
- Department of Physics, Panjab University, Chandigarh 160 014, India
| | - D Bhattarai
- University of Mississippi, University, Mississippi 38677, USA
| | - B Bhuyan
- Department of Physics, IIT Guwahati, Guwahati 781 039, India
| | - J Bian
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - A C Booth
- Particle Physics Research Centre, Department of Physics and Astronomy, Queen Mary University of London, London E1 4NS, United Kingdom
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Bowles
- Indiana University, Bloomington, Indiana 47405, USA
| | - B Brahma
- Department of Physics, IIT Hyderabad, Hyderabad 502 205, India
| | - C Bromberg
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - N Buchanan
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - A Butkevich
- Institute for Nuclear Research of Russia, Academy of Sciences 7a, 60th October Anniversary prospect, Moscow 117312, Russia
| | - S Calvez
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E Catano-Mur
- Department of Physics, William & Mary, Williamsburg, Virginia 23187, USA
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Chatla
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - R Chirco
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - B C Choudhary
- Department of Physics and Astrophysics, University of Delhi, Delhi 110007, India
| | - A Christensen
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - T E Coan
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - M Colo
- Department of Physics, William & Mary, Williamsburg, Virginia 23187, USA
| | - L Cremonesi
- Particle Physics Research Centre, Department of Physics and Astronomy, Queen Mary University of London, London E1 4NS, United Kingdom
| | - G S Davies
- Indiana University, Bloomington, Indiana 47405, USA
- University of Mississippi, University, Mississippi 38677, USA
| | - P F Derwent
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P Ding
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - Z Djurcic
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M Dolce
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - D Doyle
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - D Dueñas Tonguino
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - E C Dukes
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - R Ehrlich
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Elkins
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - E Ewart
- Indiana University, Bloomington, Indiana 47405, USA
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - P Filip
- Institute of Physics, The Czech Academy of Sciences, 182 21 Prague, Czech Republic
| | - J Franc
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - M J Frank
- Department of Physics, University of South Alabama, Mobile, Alabama 36688, USA
| | - H R Gallagher
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - R Gandrajula
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Gao
- Department of Physics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - A Giri
- Department of Physics, IIT Hyderabad, Hyderabad 502 205, India
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, Goiânia, Goiás 74690-900, Brazil
| | - M C Goodman
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - V Grichine
- Nuclear Physics and Astrophysics Division, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - M Groh
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
- Indiana University, Bloomington, Indiana 47405, USA
| | - R Group
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Guo
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Habig
- Department of Physics and Astronomy, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - F Hakl
- Institute of Computer Science, The Czech Academy of Sciences, 182 07 Prague, Czech Republic
| | - A Hall
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - H Hausner
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - M He
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - K Heller
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - V Hewes
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A Himmel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - B Jargowsky
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - J Jarosz
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - F Jediny
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - C Johnson
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - M Judah
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
- Department of Physics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - I Kakorin
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - D M Kaplan
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - A Kalitkina
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - R Keloth
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - O Klimov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - L W Koerner
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - L Kolupaeva
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - S Kotelnikov
- Nuclear Physics and Astrophysics Division, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - R Kralik
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - Ch Kullenberg
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - M Kubu
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - A Kumar
- Department of Physics, Panjab University, Chandigarh 160 014, India
| | - C D Kuruppu
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - V Kus
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - T Lackey
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
- Indiana University, Bloomington, Indiana 47405, USA
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Lasorak
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - J Lesmeister
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - S Lin
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - A Lister
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J Liu
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - M Lokajicek
- Institute of Physics, The Czech Academy of Sciences, 182 21 Prague, Czech Republic
| | - J M C Lopez
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - R Mahji
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - S Magill
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | | | - W A Mann
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - M T Manoharan
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - M L Marshak
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - M Martinez-Casales
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - V Matveev
- Institute for Nuclear Research of Russia, Academy of Sciences 7a, 60th October Anniversary prospect, Moscow 117312, Russia
| | - B Mayes
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - M D Messier
- Indiana University, Bloomington, Indiana 47405, USA
| | - H Meyer
- Department of Mathematics, Statistics, and Physics, Wichita State University, Wichita, Kansas 67206, USA
| | - T Miao
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - V Mikola
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - W H Miller
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - S Mishra
- Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 221 005, India
| | - S R Mishra
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Mislivec
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - R Mohanta
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - A Moren
- Department of Physics and Astronomy, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - A Morozova
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - W Mu
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Mualem
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Muether
- Department of Mathematics, Statistics, and Physics, Wichita State University, Wichita, Kansas 67206, USA
| | - K Mulder
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - D Naples
- Department of Physics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - A Nath
- Department of Physics, IIT Guwahati, Guwahati 781 039, India
| | - N Nayak
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - S Nelleri
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - J K Nelson
- Department of Physics, William & Mary, Williamsburg, Virginia 23187, USA
| | - R Nichol
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - E Niner
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Norman
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Norrick
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - T Nosek
- Charles University, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - H Oh
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - T Olson
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - J Ott
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - A Pal
- National Institute of Science Education and Research, Khurda 752050, Odisha, India
| | - J Paley
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Panda
- National Institute of Science Education and Research, Khurda 752050, Odisha, India
| | - R B Patterson
- California Institute of Technology, Pasadena, California 91125, USA
| | - G Pawloski
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - O Petrova
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - R Petti
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Pobedimov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - J C C Porter
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - A Rafique
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - L R Prais
- University of Mississippi, University, Mississippi 38677, USA
| | - V Raj
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Rajaoalisoa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - B Ramson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - B Rebel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - P Rojas
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - P Roy
- Department of Mathematics, Statistics, and Physics, Wichita State University, Wichita, Kansas 67206, USA
| | - V Ryabov
- Nuclear Physics and Astrophysics Division, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - O Samoylov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - M C Sanchez
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - S Sánchez Falero
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - P Shanahan
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Shukla
- Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 221 005, India
| | - A Sheshukov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - I Singh
- Department of Physics and Astrophysics, University of Delhi, Delhi 110007, India
| | - P Singh
- Department of Physics and Astrophysics, University of Delhi, Delhi 110007, India
- Particle Physics Research Centre, Department of Physics and Astronomy, Queen Mary University of London, London E1 4NS, United Kingdom
| | - V Singh
- Department of Physics, Institute of Science, Banaras Hindu University, Varanasi 221 005, India
| | - E Smith
- Indiana University, Bloomington, Indiana 47405, USA
| | - J Smolik
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - P Snopok
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - N Solomey
- Department of Mathematics, Statistics, and Physics, Wichita State University, Wichita, Kansas 67206, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - K Soustruznik
- Charles University, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - M Strait
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - L Suter
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sutton
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Swain
- National Institute of Science Education and Research, Khurda 752050, Odisha, India
| | - C Sweeney
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - A Sztuc
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - R L Talaga
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Tapia Oregui
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Tas
- Charles University, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - B N Temizel
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - T Thakore
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - R B Thayyullathil
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - J Thomas
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E Tiras
- Department of Physics, Erciyes University, Kayseri 38030, Turkey
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - J Tripathi
- Department of Physics, Panjab University, Chandigarh 160 014, India
| | - J Trokan-Tenorio
- Department of Physics, William & Mary, Williamsburg, Virginia 23187, USA
| | - Y Torun
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - J Urheim
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vahle
- Department of Physics, William & Mary, Williamsburg, Virginia 23187, USA
| | - Z Vallari
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Vasel
- Indiana University, Bloomington, Indiana 47405, USA
| | - T Vrba
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - M Wallbank
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - T K Warburton
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - M Wetstein
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - D Whittington
- Indiana University, Bloomington, Indiana 47405, USA
- Department of Physics, Syracuse University, Syracuse New York 13210, USA
| | | | - T Wieber
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - J Wolcott
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - W Wu
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - Y Xiao
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - B Yaeggy
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A Yallappa Dombara
- Department of Physics, Syracuse University, Syracuse New York 13210, USA
| | - A Yankelevich
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - K Yonehara
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Yu
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - Y Yu
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - S Zadorozhnyy
- Institute for Nuclear Research of Russia, Academy of Sciences 7a, 60th October Anniversary prospect, Moscow 117312, Russia
| | - J Zalesak
- Institute of Physics, The Czech Academy of Sciences, 182 21 Prague, Czech Republic
| | - Y Zhang
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Zwaska
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| |
Collapse
|
10
|
Antonelli L, Ardizzone D, Ravi P, Sweeney C, Bagrodia A, Mego M, Douglawi A, Campanelli Palmer T, Nazzani S, Giannatempo P, Franza A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Naoun N, Javaud C, Fizazi K, Cary C, Fankhauser C. Risk of residual teratoma after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: A multi-institutional retrospective cohort study. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02456-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
11
|
Wong AKH, Paton M, Dalbahadur P, Williams AM, Semakula F, Sweeney C, Smith M, Parsons IT. Occupational health screening during Gurkha Central Selection: a retrospective cohort study. BMJ Mil Health 2022. [DOI: 10.1136/military-2022-002158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
ObjectiveThe selection process to the British Army’s Brigade of Gurkhas is rigorous, demanding and competitive. The ethos of recruitment to the Gurkhas is grounded in an overarching tenant: that selection is free, fair and transparent. The aim of this study was to retrospectively review reasons for potential recruits (PRs) to be deemed medically unsuitable or deferred suitability on medical grounds for selection to the Brigade of Gurkhas.MethodsA retrospective review was conducted by extracted data from published post-exercise reports for the past four years to ascertain numbers of PRs deemed medically fit, medically unsuitable or deferred suitability on medical grounds. The International Classification of Disease version 11 (ICD-11) codes were retrospectively assigned to code medical reasons for non-progression. Rates of medical non-progression were compared by year.ResultsA total of 3154 PRs were analysed between 2018 and 2021. There was no significant difference between PRs deemed medically fit and those deemed medically suitable or deferred on medical grounds over the study period (p=0.351). There was a significant difference in the ratio of PRs deferred on medical grounds and those deemed medically unsuitable over the study period (p<0.05).ConclusionSelection to the Gurkhas is extremely competitive. These data demonstrate that, overall, reasons for medical deferral or unsuitability have remained constant despite the impact of a global pandemic. These data reinforce the central tenant of Gurkha selection; that it continues to be free, fair, and transparent.
Collapse
|
12
|
Friedman C, Swanton C, Spigel D, Bose R, Burris H, Yu W, Wang Y, Malato J, Price R, Darbonne W, Szado T, Schulze K, Sweeney C, Hainsworth J, Meric-Bernstam F, Kurzrock R. 66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Millar MM, Edwards SL, Herget KA, Orleans B, Ofori‐Atta BS, Kirchhoff AC, Carter ME, Nagata M, Sweeney C. Adherence to Guideline-Recommended cancer screening among Utah cancer survivors. Cancer Med 2022; 12:3543-3554. [PMID: 36029153 PMCID: PMC9939153 DOI: 10.1002/cam4.5168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 04/04/2022] [Accepted: 08/08/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Adherence to cancer screening is important for cancer survivors because they are at high risk of subsequent cancer diagnoses or recurrence. We assessed adherence to breast, cervical, and colorectal cancer-(CRC)-screening guidelines and evaluated demographic disparities among a population-based sample of survivors. METHODS A representative sample of Utah survivors diagnosed from 2012-2018 with any reportable invasive cancer was selected from central cancer registry records for a survey about survivorship needs. We estimated the proportion of eligible survivors adhering to U.S. Preventive Services Task Force screening guidelines and calculated risk ratios and 95% confidence intervals. Analyses were age-adjusted and weighted to account for sample design and nonresponse. RESULTS And 1421 survivors completed the survey (57.2% response rate). Screening adherence was 74.4% for breast, 69.4% for cervical, and 79.7% for CRC. Rural residents were more likely to adhere to breast cancer screening than urban residents (86.1% vs. 72.7%; adjusted RR = 1.19, CI = 1.05, 1.36). Higher educational attainment was associated with increased adherence to cervical and colorectal cancer screening. Younger age was associated with greater adherence to cervical cancer screening (p = 0.006) but lower adherence to CRC screening (p = 0.003). CRC screening adherence was lower among the uninsured and those without a primary care provider (45.6%) compared to those with a regular provider (83.0%; adjusted RR = 0.57, CI = 0.42, 0.79). CONCLUSIONS Surveys based on samples from central cancer registries can provide population estimates to inform cancer control. Findings demonstrate work is needed to ensure all Utah cancer survivors obtain recommended cancer screenings. Efforts should focus particularly on increasing uptake of breast and cervical cancer screening and reducing demographic disparities in CRC screening. PRECIS Despite high risk for subsequent cancer diagnosis, Utah cancer survivors are not all obtaining recommended breast, cervical, and colorectal cancer screenings. This presents a significant healthcare gap.
Collapse
Affiliation(s)
- Morgan M. Millar
- Utah Cancer RegistryUniversity of UtahSalt Lake CityUtahUSA,Division of EpidemiologyUniversity of UtahSalt Lake CityUtahUSA,Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUtahUSA
| | | | | | - Brian Orleans
- Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUtahUSA
| | | | - Anne C. Kirchhoff
- Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUtahUSA,Department of PediatricsUniversity of UtahSalt Lake CityUtahUSA
| | | | - Marie Nagata
- Breast and Cervical Cancer Early Detection Program, Utah Department of Health and Human ServicesSalt Lake CityUtahUSA
| | - Carol Sweeney
- Utah Cancer RegistryUniversity of UtahSalt Lake CityUtahUSA,Division of EpidemiologyUniversity of UtahSalt Lake CityUtahUSA,Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUtahUSA
| |
Collapse
|
14
|
Acero MA, Adamson P, Aliaga L, Anfimov N, Antoshkin A, Arrieta-Diaz E, Asquith L, Aurisano A, Back A, Backhouse C, Baird M, Balashov N, Baldi P, Bambah BA, Bashar S, Bays K, Bernstein R, Bhatnagar V, Bhuyan B, Bian J, Blair J, Booth AC, Bowles R, Bromberg C, Buchanan N, Butkevich A, Calvez S, Carroll TJ, Catano-Mur E, Choudhary BC, Christensen A, Coan TE, Colo M, Cremonesi L, Davies GS, Derwent PF, Ding P, Djurcic Z, Dolce M, Doyle D, Dueñas Tonguino D, Dukes EC, Duyang H, Edayath S, Ehrlich R, Elkins M, Ewart E, Feldman GJ, Filip P, Franc J, Frank MJ, Gallagher HR, Gandrajula R, Gao F, Giri A, Gomes RA, Goodman MC, Grichine V, Groh M, Group R, Guo B, Habig A, Hakl F, Hall A, Hartnell J, Hatcher R, Hausner H, Heller K, Hewes J, Himmel A, Holin A, Huang J, Jargowsky B, Jarosz J, Jediny F, Johnson C, Judah M, Kakorin I, Kalra D, Kalitkina A, Kaplan DM, Keloth R, Klimov O, Koerner LW, Kolupaeva L, Kotelnikov S, Kralik R, Kullenberg C, Kubu M, Kumar A, Kuruppu CD, Kus V, Lackey T, Lasorak P, Lang K, Lesmeister J, Lin S, Lister A, Liu J, Lokajicek M, Magill S, Manrique Plata M, Mann WA, Marshak ML, Martinez-Casales M, Matveev V, Mayes B, Méndez DP, Messier MD, Meyer H, Miao T, Miller WH, Mishra SR, Mislivec A, Mohanta R, Moren A, Morozova A, Mu W, Mualem L, Muether M, Mulder K, Naples D, Nayak N, Nelson JK, Nichol R, Niner E, Norman A, Norrick A, Nosek T, Oh H, Olshevskiy A, Olson T, Ott J, Paley J, Patterson RB, Pawloski G, Petrova O, Petti R, Phan DD, Plunkett RK, Porter JCC, Rafique A, Raj V, Rajaoalisoa M, Ramson B, Rebel B, Rojas P, Ryabov V, Samoylov O, Sanchez MC, Sánchez Falero S, Shanahan P, Sheshukov A, Singh P, Singh V, Smith E, Smolik J, Snopok P, Solomey N, Sousa A, Soustruznik K, Strait M, Suter L, Sutton A, Swain S, Sweeney C, Tapia Oregui B, Tas P, Thakore T, Thayyullathil RB, Thomas J, Tiras E, Tripathi J, Trokan-Tenorio J, Tsaris A, Torun Y, Urheim J, Vahle P, Vallari Z, Vasel J, Vokac P, Vrba T, Wallbank M, Warburton TK, Wetstein M, Whittington D, Wickremasinghe DA, Wojcicki SG, Wolcott J, Wu W, Xiao Y, Yallappa Dombara A, Yonehara K, Yu S, Yu Y, Zadorozhnyy S, Zalesak J, Zhang Y, Zwaska R. Search for Active-Sterile Antineutrino Mixing Using Neutral-Current Interactions with the NOvA Experiment. Phys Rev Lett 2021; 127:201801. [PMID: 34860065 DOI: 10.1103/physrevlett.127.201801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 09/30/2021] [Indexed: 06/13/2023]
Abstract
This Letter reports results from the first long-baseline search for sterile antineutrinos mixing in an accelerator-based antineutrino-dominated beam. The rate of neutral-current interactions in the two NOvA detectors, at distances of 1 and 810 km from the beam source, is analyzed using an exposure of 12.51×10^{20} protons-on-target from the NuMI beam at Fermilab running in antineutrino mode. A total of 121 of neutral-current candidates are observed at the far detector, compared to a prediction of 122±11(stat.)±15(syst.) assuming mixing only between three active flavors. No evidence for ν[over ¯]_{μ}→ν[over ¯]_{s} oscillation is observed. Interpreting this result within a 3+1 model, constraints are placed on the mixing angles θ_{24}<25° and θ_{34}<32° at the 90% C.L. for 0.05 eV^{2}≤Δm_{41}^{2}≤0.5 eV^{2}, the range of mass splittings that produces no significant oscillations at the near detector. These are the first 3+1 confidence limits set using long-baseline accelerator antineutrinos.
Collapse
Affiliation(s)
- M A Acero
- Universidad del Atlantico, Carrera 30 No. 8-49, Puerto Colombia, Atlantico, Colombia
| | - P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Aliaga
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Anfimov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - A Antoshkin
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - E Arrieta-Diaz
- Universidad del Magdalena, Carrera 32 No 22 - 08 Santa Marta, Colombia
| | - L Asquith
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A Back
- Indiana University, Bloomington, Indiana 47405, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - C Backhouse
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - M Baird
- Indiana University, Bloomington, Indiana 47405, USA
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Balashov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - P Baldi
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - B A Bambah
- School of Physics, University of Hyderabad, Hyderabad, 500 046, India
| | - S Bashar
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - K Bays
- California Institute of Technology, Pasadena, California 91125, USA
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - R Bernstein
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - V Bhatnagar
- Department of Physics, Panjab University, Chandigarh, 160 014, India
| | - B Bhuyan
- Department of Physics, IIT Guwahati, Guwahati, 781 039, India
| | - J Bian
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - J Blair
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - A C Booth
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Bowles
- Indiana University, Bloomington, Indiana 47405, USA
| | - C Bromberg
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - N Buchanan
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - A Butkevich
- Institute for Nuclear Research of Russia, Academy of Sciences 7a, 60th October Anniversary prospect, Moscow 117312, Russia
| | - S Calvez
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - T J Carroll
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E Catano-Mur
- Department of Physics, William and Mary, Williamsburg, Virginia 23187, USA
| | - B C Choudhary
- Department of Physics and Astrophysics, University of Delhi, Delhi 110007, India
| | - A Christensen
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - T E Coan
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - M Colo
- Department of Physics, William and Mary, Williamsburg, Virginia 23187, USA
| | - L Cremonesi
- School of Physics and Astronomy, Queen Mary University of London, London E1 4NS, United Kingdom
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - G S Davies
- Indiana University, Bloomington, Indiana 47405, USA
- University of Mississippi, University, Mississippi 38677, USA
| | - P F Derwent
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P Ding
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - Z Djurcic
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M Dolce
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - D Doyle
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - D Dueñas Tonguino
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - E C Dukes
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Duyang
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - S Edayath
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - R Ehrlich
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Elkins
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - E Ewart
- Indiana University, Bloomington, Indiana 47405, USA
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - P Filip
- Institute of Physics, The Czech Academy of Sciences, 182 21 Prague, Czech Republic
| | - J Franc
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - M J Frank
- Department of Physics, University of South Alabama, Mobile, Alabama 36688, USA
| | - H R Gallagher
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - R Gandrajula
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Gao
- Department of Physics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - A Giri
- Department of Physics, IIT Hyderabad, Hyderabad, 502 205, India
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, Goiánia, Goiás, 74690-900, Brazil
| | - M C Goodman
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - V Grichine
- Nuclear Physics and Astrophysics Division, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - M Groh
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
- Indiana University, Bloomington, Indiana 47405, USA
| | - R Group
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Guo
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Habig
- Department of Physics and Astronomy, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - F Hakl
- Institute of Computer Science, The Czech Academy of Sciences, 182 07 Prague, Czech Republic
| | - A Hall
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - H Hausner
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - K Heller
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - J Hewes
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A Himmel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Holin
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - J Huang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - B Jargowsky
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - J Jarosz
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - F Jediny
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - C Johnson
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - M Judah
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
- Department of Physics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - I Kakorin
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - D Kalra
- Department of Physics, Panjab University, Chandigarh, 160 014, India
| | - A Kalitkina
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - D M Kaplan
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - R Keloth
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - O Klimov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - L W Koerner
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - L Kolupaeva
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - S Kotelnikov
- Nuclear Physics and Astrophysics Division, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - R Kralik
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - Ch Kullenberg
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - M Kubu
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - A Kumar
- Department of Physics, Panjab University, Chandigarh, 160 014, India
| | - C D Kuruppu
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - V Kus
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - T Lackey
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Lasorak
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - K Lang
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - J Lesmeister
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - S Lin
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - A Lister
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J Liu
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - M Lokajicek
- Institute of Physics, The Czech Academy of Sciences, 182 21 Prague, Czech Republic
| | - S Magill
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | | | - W A Mann
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - M Martinez-Casales
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - V Matveev
- Institute for Nuclear Research of Russia, Academy of Sciences 7a, 60th October Anniversary prospect, Moscow 117312, Russia
| | - B Mayes
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - D P Méndez
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - M D Messier
- Indiana University, Bloomington, Indiana 47405, USA
| | - H Meyer
- Department of Mathematics, Statistics, and Physics, Wichita State University, Wichita, Kansas 67206, USA
| | - T Miao
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - W H Miller
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - S R Mishra
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Mislivec
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - R Mohanta
- School of Physics, University of Hyderabad, Hyderabad, 500 046, India
| | - A Moren
- Department of Physics and Astronomy, University of Minnesota Duluth, Duluth, Minnesota 55812, USA
| | - A Morozova
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - W Mu
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Mualem
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Muether
- Department of Mathematics, Statistics, and Physics, Wichita State University, Wichita, Kansas 67206, USA
| | - K Mulder
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - D Naples
- Department of Physics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - N Nayak
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - J K Nelson
- Department of Physics, William and Mary, Williamsburg, Virginia 23187, USA
| | - R Nichol
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - E Niner
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Norman
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Norrick
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - T Nosek
- Charles University, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - H Oh
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - A Olshevskiy
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - T Olson
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - J Ott
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - J Paley
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R B Patterson
- California Institute of Technology, Pasadena, California 91125, USA
| | - G Pawloski
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - O Petrova
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - R Petti
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - D D Phan
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J C C Porter
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - A Rafique
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - V Raj
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Rajaoalisoa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - B Ramson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - B Rebel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - P Rojas
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523-1875, USA
| | - V Ryabov
- Nuclear Physics and Astrophysics Division, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - O Samoylov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - M C Sanchez
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - S Sánchez Falero
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - P Shanahan
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sheshukov
- Joint Institute for Nuclear Research, Dubna, Moscow region 141980, Russia
| | - P Singh
- Department of Physics and Astrophysics, University of Delhi, Delhi 110007, India
| | - V Singh
- Department of Physics, Institute of Science, Banaras Hindu University, Varanasi, 221 005, India
| | - E Smith
- Indiana University, Bloomington, Indiana 47405, USA
| | - J Smolik
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - P Snopok
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - N Solomey
- Department of Mathematics, Statistics, and Physics, Wichita State University, Wichita, Kansas 67206, USA
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - K Soustruznik
- Charles University, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - M Strait
- School of Physics and Astronomy, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, USA
| | - L Suter
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sutton
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Swain
- National Institute of Science Education and Research, Khurda, 752050, Odisha, India
| | - C Sweeney
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - B Tapia Oregui
- Department of Physics, University of Texas at Austin, Austin, Texas 78712, USA
| | - P Tas
- Charles University, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - T Thakore
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - R B Thayyullathil
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - J Thomas
- Physics and Astronomy Department, University College London, Gower Street, London WC1E 6BT, United Kingdom
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E Tiras
- Department of Physics, Erciyes University, Kayseri 38030, Turkey
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - J Tripathi
- Department of Physics, Panjab University, Chandigarh, 160 014, India
| | - J Trokan-Tenorio
- Department of Physics, William and Mary, Williamsburg, Virginia 23187, USA
| | - A Tsaris
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - Y Torun
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - J Urheim
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vahle
- Department of Physics, William and Mary, Williamsburg, Virginia 23187, USA
| | - Z Vallari
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Vasel
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vokac
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - T Vrba
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - M Wallbank
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - T K Warburton
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - M Wetstein
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - D Whittington
- Indiana University, Bloomington, Indiana 47405, USA
- Department of Physics, Syracuse University, Syracuse New York 13210, USA
| | | | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - J Wolcott
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - W Wu
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - Y Xiao
- Department of Physics and Astronomy, University of California at Irvine, Irvine, California 92697, USA
| | - A Yallappa Dombara
- Department of Physics, Syracuse University, Syracuse New York 13210, USA
| | - K Yonehara
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Yu
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - Y Yu
- Illinois Institute of Technology, Chicago Illinois 60616, USA
| | - S Zadorozhnyy
- Institute for Nuclear Research of Russia, Academy of Sciences 7a, 60th October Anniversary prospect, Moscow 117312, Russia
| | - J Zalesak
- Institute of Physics, The Czech Academy of Sciences, 182 21 Prague, Czech Republic
| | - Y Zhang
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Zwaska
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| |
Collapse
|
15
|
Sutera P, Van der Eecken K, Kishan A, Hamid A, Grist E, Attard G, Lotan T, Mendes A, Sweeney C, Paller C, Carducci M, Ross A, Pienta K, Feng F, Eisenberger M, Antonarakis E, Ost P, Tran P, Deek M. Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Herrera-Restrepo O, Ghaswalla P, Davis K, Sweeney C, Davenport E, Andani A, Buck PO. What can Europe learn from HCP knowledge and attitudes towards hepatitis A vaccination in the US? Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab165.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
An estimated >100 million new hepatitis A (hepA) infections occur annually worldwide. Centres for disease control and prevention reported 38795 hepA cases in the US since 2016, and 4475 outbreak-confirmed cases in Europe between 2016-2018. HepA outbreaks resulted mainly from person-to-person contact, especially among homeless, illegal drug users (IDU) and men who have sex with men (MSM). In 2020, we surveyed US health care providers (HCPs) to understand their knowledge and attitudes towards hepA vaccination in these populations at higher risk of infection and complications.
Methods
This was a cross-sectional, web-based survey of 400 HCPs (primary care providers, nurse practitioners, gastroenterologists, internal medicine and infectious disease specialists [IDs], emergency room physicians [ERs]) who had recommended and/or administered hepA vaccines to ≥ 19-year-olds.
Results
85% of 371 HCPs reported recommending hepA vaccine to homeless, 87% of 393 to IDU and 83% of 397 to MSM, although vaccination may not actually occur after recommendation. Results varied by specialty, 16% fewer ERs than IDs reported recommending the vaccine in these at-risk populations. Moreover, 64%, 75% and 71% of all (400) HCPs reported extremely important that homeless, IDU and MSM, respectively, get vaccinated for hepA, while 6%, 7% and 8% of all HCPs reported this as slightly, or not important. Reasons for not recommending hepA vaccine to homeless, IDU and MSM included uncertainty on guidelines (reported by 22/56, 24/50 and 29/66 HCPs, respectively) and low risk of infection (reported by 20/56, 30/50 and 27/66 HCPs, respectively).
Conclusions
Despite recent hepA outbreaks and strengthened recommendations for vaccination in at-risk populations, knowledge gaps persist among US HCPs. This survey may motivate European countries to reinforce national hepA vaccination recommendations and, in parallel, consider efforts to raise vaccination awareness.
Funding
GlaxoSmithKline Biologicals SA
Key messages
Education on hepatitis A vaccination recommendations in at-risk populations is needed. Health care providers’ vaccination knowledge plays a critical role to control the hepatitis A outbreak in the US and preventing hepatitis A in Europe.
Collapse
Affiliation(s)
| | - P Ghaswalla
- Vaccines, US Health Outcomes and Epidemiology, GSK, Philadelphia, USA
| | - K Davis
- Surveys and Observational Studies, RTI Health Solutions, Research Triangle Park, USA
| | - C Sweeney
- Surveys and Observational Studies, RTI Health Solutions, Research Triangle Park, USA
| | - E Davenport
- Surveys and Observational Studies, RTI Health Solutions, Research Triangle Park, USA
| | - A Andani
- Vaccines, Global Medical Affairs, GSK, Wavre, Belgium
| | - PO Buck
- Vaccines, US Health Outcomes and Epidemiology, GSK, Philadelphia, USA
| |
Collapse
|
17
|
Sternberg C, Bracarda S, de Bono J, Sweeney C, Chi K, Olmos D, Sandhu S, Massard C, Garcia J, Schenkel F, Chen G, Harris A, Hinton H, Matsubara N. 585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
18
|
Wei Y, Shrestha R, Pal S, Gerken T, Feng S, McNelis J, Singh D, Thornton MM, Boyer AG, Shook MA, Chen G, Baier BC, Barkley ZR, Barrick JD, Bennett JR, Browell EV, Campbell JF, Campbell LJ, Choi Y, Collins J, Dobler J, Eckl M, Fiehn A, Fried A, Digangi JP, Barton‐Grimley R, Halliday H, Klausner T, Kooi S, Kostinek J, Lauvaux T, Lin B, McGill MJ, Meadows B, Miles NL, Nehrir AR, Nowak JB, Obland M, O’Dell C, Fao RMP, Richardson SJ, Richter D, Roiger A, Sweeney C, Walega J, Weibring P, Williams CA, Yang MM, Zhou Y, Davis KJ. Atmospheric Carbon and Transport - America (ACT-America) Data Sets: Description, Management, and Delivery. Earth Space Sci 2021; 8:e2020EA001634. [PMID: 34435081 PMCID: PMC8365738 DOI: 10.1029/2020ea001634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 04/19/2021] [Accepted: 05/09/2021] [Indexed: 06/13/2023]
Abstract
The ACT-America project is a NASA Earth Venture Suborbital-2 mission designed to study the transport and fluxes of greenhouse gases. The open and freely available ACT-America data sets provide airborne in situ measurements of atmospheric carbon dioxide, methane, trace gases, aerosols, clouds, and meteorological properties, airborne remote sensing measurements of aerosol backscatter, atmospheric boundary layer height and columnar content of atmospheric carbon dioxide, tower-based measurements, and modeled atmospheric mole fractions and regional carbon fluxes of greenhouse gases over the Central and Eastern United States. We conducted 121 research flights during five campaigns in four seasons during 2016-2019 over three regions of the US (Mid-Atlantic, Midwest and South) using two NASA research aircraft (B-200 and C-130). We performed three flight patterns (fair weather, frontal crossings, and OCO-2 underflights) and collected more than 1,140 h of airborne measurements via level-leg flights in the atmospheric boundary layer, lower, and upper free troposphere and vertical profiles spanning these altitudes. We also merged various airborne in situ measurements onto a common standard sampling interval, which brings coherence to the data, creates geolocated data products, and makes it much easier for the users to perform holistic analysis of the ACT-America data products. Here, we report on detailed information of data sets collected, the workflow for data sets including storage and processing of the quality controlled and quality assured harmonized observations, and their archival and formatting for users. Finally, we provide some important information on the dissemination of data products including metadata and highlights of applications of ACT-America data sets.
Collapse
|
19
|
McCarty R, Collin L, Grieshober L, Ou J, Sweeney C, Barnard ME, Doherty JA. Abstract 795: County-level radon and smoking exposure and lung cancer risk by histotype, sex, and race/ethnicity. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Radon and smoking synergistically increase risk of lung cancer, particularly for small cell and squamous cell carcinoma; however, associations by sex and race/ethnicity have not been reported.
Methods: We used data from the Behavioral Risk Factor Surveillance System (BRFSS), Environmental Protection Agency (EPA), and SEER21, excluding Alaska, to investigate the associations between county-level radon and smoking prevalence with lung cancer incidence by histotype, sex, and race/ethnicity (2006-2016). We only examined Non-Hispanic (NH) White and NH Black race/ethnicities due to the small proportion of cases from other groups. We used tertiles of sex-specific smoking prevalence estimates (1996-2000) from the BRFSS and EPA-defined radon zones of low, moderate, and high, to categorize 729 counties by both radon levels and smoking prevalence by sex. We fit generalized linear models using modified Poisson regression with Huber-White robust standard errors to compute rate ratios (RRs) and 95% confidence intervals (CIs) associating radon exposure, stratified by smoking tertile with histotype-specific lung cancer incidence.
Results: The smoking prevalence captured by each tertile was considerably lower for women (Low=9.0-22.4%, Moderate>22.4-25.3, High>25.3-36.6) than men (Low=14.4-27.3, Moderate>27.3-31.6, High>31.6-40.3). Among women, we observed the most pronounced associations between high radon and lung cancer risk compared to low radon within the highest female smoking tertile. These associations were evident among NH Black women, particularly for small cell carcinoma (RR=1.34, 95% CI: 1.05-1.71) and squamous cell carcinoma (RR=1.41, CI: 1.14-1.74), but were smaller and non-significant among NH White women. For men, the associations with radon were observed even in counties with low male smoking prevalence. For example, in counties in the lowest tertile of male smokers, associations of high radon with squamous cell and small cell lung cancer were observed among NH Black men (RR=1.27, 95% CI: 1.11-1.44, and RR=1.37, 95% CI:1.15-1.63, respectively) and NH White men (RR=1.18, 95% CI: 1.11-1.26, and RR=1.20, 95% CI: 1.11-1.29, respectively). When we considered that the percent of current smokers in the lowest smoking tertile for men overlaps the highest tertile for women, we observed radon-associated small cell and squamous cell lung cancer risk for NH Black men and women at comparable absolute smoking prevalence, and a similar but attenuated pattern in NH White men and women.
Discussion: While our analysis is limited by the ecological nature of the radon and smoking data, this research suggests that previously reported associations between radon and smoking exposure and histotype-specific lung cancer risk may differ by race and sex. Further research is needed to understand the impact of combined radon and smoking exposure on lung cancer risk in other racial and ethnic groups.
Citation Format: Rachel McCarty, Lindsay Collin, Laurie Grieshober, Judy Ou, Carol Sweeney, Mollie E. Barnard, Jennifer A. Doherty. County-level radon and smoking exposure and lung cancer risk by histotype, sex, and race/ethnicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 795.
Collapse
Affiliation(s)
- Rachel McCarty
- 1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Lindsay Collin
- 1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | | | - Judy Ou
- 1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - Carol Sweeney
- 2Department of Population Health Sciences, School of Medicine, University of Utah, Salt Lake City, UT
| | | | | |
Collapse
|
20
|
Husni ME, Bozyczko M, Wolin D, Sweeney C, Davenport E, Hass S, Yi E, Hur P, Grinnell-Merrick L. POS1060 A PROSPECTIVE, LONGITUDINAL STUDY TO EVALUATE REAL-WORLD PATIENT EXPERIENCES AND TREATMENT SATISFACTION WITH SECUKINUMAB FOR PSORIATIC ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Psoriatic arthritis (PsA) is an inflammatory disease that impairs quality of life. Despite therapeutic advances, up to a third of patients do not respond or are unable to sustain a treatment response. Thus, data on patient treatment experience in PsA is critical.Objectives:To assess real-world experiences of patients with PsA treated with secukinumab.Methods:This is an ongoing 12-month, prospective, longitudinal, web-based survey study of patients with PsA initiating secukinumab. Patient demographics and medical history are collected at baseline using a rheumatologist case report form. Patient experience data are collected at baseline, 3, 6, 9, and 12 months by patient surveys. The primary endpoint is change in the Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID12) from baseline to 3 months. In addition, this study will explore other changes at 3 months, including PsA symptoms, treatment satisfaction with secukinumab, and other patient-reported outcome measures. Baseline and available month 3 data from patients enrolled to date were analyzed descriptively.Results:Baseline demographic and medical history data were available for 72 patients; 32 (44.4%) were male, 59 (81.9%) were White, and 15 (20.8%) reported modifying their diet because of PsA. The mean (SD) time since symptom onset (n = 29) and since PsA diagnosis (n = 53) was 56.3 (45.6) and 34.4 (44.7) months, respectively. More than half of the patients who started treatment with secukinumab were biologic experienced (38/62; 61.3%). Primary and secondary loss of effectiveness were the main reasons for previous biologic discontinuation (Table 1). At 3 months (n = 49), the mean (SD) PsAID12 change from baseline was –1.8 (1.8) points. Additionally, 24.5% of patients reported their PsA symptoms to be “much better,” 40.8% reported “moderately better,” and 32.7% “a little better” compared with baseline; none reported “no change” or worsened symptoms. On a scale of 1-10, patients rated their overall satisfaction with secukinumab treatment at month 3 with a mean (SD) score of 6.8 (2.1). Patients were also highly satisfied with their symptom improvement, speed to symptom improvement, and the mode and frequency of secukinumab administration (Table 1).Table 1.Summary of Prior PsA Treatment and Treatment Satisfaction with Secukinumab at Month 3Physician-reported treatment characteristicsBaseline measure(N = 62)Most recent PsA biologic prior to secukinumab, n (%)n = 31Adalimumab12 (38.7)Certolizumab pegol8 (25.8)Etanercept6 (19.4)Infliximab, including -dyyb3 (9.7)Golimumab1 (3.2)Unknown/not sure1 (3.2)Primary reasons for discontinuing previous PsA biologic treatment, n (%)an = 30Primary and secondary loss of effectiveness25 (83.3)Disease progression6 (20.0)Worsening of or new comorbidities1 (3.3)How the medication was taken2 (6.7)Adverse effects/intolerance4 (13.3)Otherb1 (3.3)Patient-reported treatment satisfaction with secukinumab, mean (SD)cMonth 3 (N = 49)Symptom improvement6.7 (2.3)Speed of symptom improvement6.9 (2.0)Dose frequency7.4 (1.9)cMethod of administration7.2 (1.5)Ease of use8.2 (1.5)Side effects, if any7.9 (1.9)Patient support services by manufacturer8.3 (1.7)PsA, psoriatic arthritis.a Rheumatologists may list > 1 reason. Data tabulated based on the number of case report forms received from rheumatologists at analysis cutoff (n = 30).b Other reasons included availability of new treatment, patient request, or family history of disease.c n = 48.Conclusion:Most patients were biologic experienced and reported primary or secondary loss of effectiveness as the main reason for discontinuation of their previous biologic. Patients reported overall symptom improvement and satisfaction with secukinumab treatment at 3 months after initiation.Disclosure of Interests:M Elaine Husni Consultant of: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, UCB, and Regeneron, Michael Bozyczko Employee of: National Psoriasis Foundation, Daniel Wolin Employee of: RTI Health Solutions, Carolyn Sweeney Employee of: RTI Health Solutions, Eric Davenport Employee of: RTI Health Solutions, Steven Hass Employee of: Novartis, Esther Yi Employee of: Novartis, Peter Hur Employee of: Novartis, Linda Grinnell-Merrick Consultant of: AbbVie, Amgen (previously Celgene), Novartis, Pfizer, and Regeneron.
Collapse
|
21
|
Cho ME, Sweeney C, Fino N, Greene T, Ramkumar N, Huang Y, Ricardo AC, Shafi T, Deo R, Anderson A, Mills KT, Cheung AK. Longitudinal Changes in Prorenin and Renin in the Chronic Renal Insufficiency Cohort. Am J Nephrol 2021; 52:141-151. [PMID: 33735863 PMCID: PMC8049970 DOI: 10.1159/000514302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 01/08/2021] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Prorenin, a precursor of renin, and renin play an important role in regulation of the renin-angiotensin system. More recently, receptor-bound prorenin has been shown to activate intracellular signaling pathways that mediate fibrosis, independent of angiotensin II. Prorenin and renin may thus be of physiologic significance in CKD, but their plasma concentrations have not been well characterized in CKD. METHODS We evaluated distribution and longitudinal changes of prorenin and renin concentrations in the plasma samples collected at follow-up years 1, 2, 3, and 5 of the Chronic Renal Insufficiency Cohort (CRIC) study, an ongoing longitudinal observational study of 3,939 adults with CKD. Descriptive statistics and multivariable regression of log-transformed values were used to describe cross-sectional and longitudinal variation and associations with participant characteristics. RESULTS A total of 3,361 CRIC participants had plasma available for analysis at year 1. The mean age (±standard deviation, SD) was 59 ± 11 years, and the mean estimated glomerular filtration rate (eGFR, ± SD) was 43 ± 17 mL/min per 1.73 m2. Median (interquartile range) values of plasma prorenin and renin at study entry were 4.4 (2.1, 8.8) ng/mL and 2.0 (0.8, 5.9) ng/dL, respectively. Prorenin and renin were positively correlated (Spearman correlation 0.51, p < 0.001) with each other. Women and non-Hispanic blacks had lower prorenin and renin values at year 1. Diabetes, lower eGFR, and use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, and diuretics were associated with higher levels. Prorenin and renin decreased by a mean of 2 and 5% per year, respectively. Non-Hispanic black race and eGFR <30 mL/min/1.73 m2 at year 1 predicted a steeper decrease in prorenin and renin over time. In addition, each increase in urinary sodium excretion by 2 SDs at year 1 increased prorenin and renin levels by 4 and 5% per year, respectively. DISCUSSION/CONCLUSIONS The cross-sectional clinical factors associated with prorenin and renin values were similar. Overall, both plasma prorenin and renin concentrations decreased over the years, particularly in those with severe CKD at study entry.
Collapse
Affiliation(s)
- Monique E. Cho
- Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT
| | - Carol Sweeney
- Division of Epidemiology, University of Utah, Salt Lake City, UT
| | - Nora Fino
- Division of Epidemiology, University of Utah, Salt Lake City, UT
| | - Tom Greene
- Division of Epidemiology, University of Utah, Salt Lake City, UT
| | - Nirupama Ramkumar
- Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT
| | - Yufeng Huang
- Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT
| | - Ana C. Ricardo
- Department of Medicine, University of Illinois, Chicago, IL
| | - Tariq Shafi
- Division of Nephrology, University of Mississippi, Jackson, MS
| | - Rajat Deo
- Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA
| | - Amanda Anderson
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA
| | - Katherine T. Mills
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA
| | - Alfred K. Cheung
- Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT
| | | |
Collapse
|
22
|
Abstract
Aim To analyze trends in Utah melanoma diagnosis and study the impact of rurality. Patients & methods State-wide melanoma incidence was calculated using Surveillance, Epidemiology, and End Results data (2005-2013). A subset of 5199 patients treated in an integrated healthcare system was further stratified for urban or rural residence. Results Early-stage tumors accounted for most of the increase in melanoma incidence over time. Age-adjusted melanoma incidence rate was higher in rural counties (46.7 vs 39.4). Anatomic site and stage did not differ between rural and urban patients. Rural patients were more commonly diagnosed by a local primary care provider. Conclusion Rurality had an impact on melanoma diagnosis in the specialty and location of the diagnosing provider.
Collapse
Affiliation(s)
| | - Carol Sweeney
- Department of Internal Medicine, Division of Epidemiology, School of Medicine, University of Utah, Salt Lake City, UT 84132, USA
| | - John Snyder
- Intermountain Healthcare, Salt Lake City, UT 84107, USA
| | - Jesse Gygi
- Intermountain Healthcare, Salt Lake City, UT 84107, USA
| | - Brad Bott
- Providence Health & Services, Irvine, CA 92612, USA
| | - Daniel Wray
- Twine Clinical Consulting, LLC, Park City, UT 84098, USA
| | | | | |
Collapse
|
23
|
Yuan Y, Van Dyke AL, Petkov VI, Hussey S, Moravec R, Altekruse SF, Sandoval M, Cress RD, Mueller LM, Mogi A, Hernandez BY, Selk FR, Lynch CF, Tucker TC, Lynch MA, Lefante C, Wu XC, Sweeney C, Doherty JA, Penberthy LS. Pathology Laboratory Policies and Procedures for Releasing Diagnostic Tissue for Cancer Research. Arch Pathol Lab Med 2021; 145:222-226. [PMID: 33501497 PMCID: PMC8135254 DOI: 10.5858/arpa.2019-0474-oa] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/31/2020] [Indexed: 11/06/2022]
Abstract
CONTEXT.— The Surveillance, Epidemiology, and End Results (SEER) cancer registry program is currently evaluating the use of archival, diagnostic, formalin-fixed, paraffin-embedded (FFPE) tissue obtained through SEER cancer registries, functioning as honest brokers for deidentified tissue and associated data. To determine the feasibility of this potential program, laboratory policies for sharing tissue for research needed to be assessed. OBJECTIVE.— To understand the willingness of pathology laboratories to share archival diagnostic tissue for cancer research and related policies. DESIGN.— Seven SEER registries administered a 27-item questionnaire to pathology laboratories within their respective registry catchment areas. Only laboratories that processed diagnostic FFPE specimens and completed the questionnaire were included in the analysis. RESULTS.— Of the 153 responding laboratories, 127 (83%) responded that they process FFPE specimens. Most (n = 88; 69%) were willing to share tissue specimens for research, which was not associated with the number of blocks processed per year by the laboratories. Most laboratories retained the specimens for at least 10 years. Institutional regulatory policies on sharing deidentified tissue varied considerably, ranging from requiring a full Institutional Review Board review to considering such use exempt from Institutional Review Board review, and 43% (55 of 127) of the laboratories did not know their terms for sharing tissue for research. CONCLUSIONS.— This project indicated a general willingness of pathology laboratories to participate in research by sharing FFPE tissue. Given the variability of research policies across laboratories, it is critical for each SEER registry to work with laboratories in their catchment area to understand such policies and state legislation regulating tissue retention and guardianship.
Collapse
Affiliation(s)
- Yao Yuan
- The Surveillance Research Program, Division of Cancer Control and Population Sciences (Yuan, Van Dyke, Petkov, Hussey, Penberthy), National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Alison L Van Dyke
- The Surveillance Research Program, Division of Cancer Control and Population Sciences (Yuan, Van Dyke, Petkov, Hussey, Penberthy), National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Valentina I Petkov
- The Surveillance Research Program, Division of Cancer Control and Population Sciences (Yuan, Van Dyke, Petkov, Hussey, Penberthy), National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Sarah Hussey
- The Surveillance Research Program, Division of Cancer Control and Population Sciences (Yuan, Van Dyke, Petkov, Hussey, Penberthy), National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Radim Moravec
- The Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis (Moravec), National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Sean F Altekruse
- The HIV/AIDS Program, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (Altekruse)
| | - Mayra Sandoval
- The Cancer Registry of Greater California, Department of Public Health, Sacramento (Sandoval, Cress)
| | - Rosemary D Cress
- The Cancer Registry of Greater California, Department of Public Health, Sacramento (Sandoval, Cress)
| | - Lloyd M Mueller
- The Connecticut Tumor Registry, State Department of Public Health, Hartford (Mueller)
| | - Alan Mogi
- The Hawaii Tumor Registry, University of Hawaii Cancer Center, Honolulu (Mogi, Hernandez)
| | - Brenda Y Hernandez
- The Hawaii Tumor Registry, University of Hawaii Cancer Center, Honolulu (Mogi, Hernandez)
| | - Freda R Selk
- The Iowa Cancer Registry, The University of Iowa, Iowa City (Selk, Lynch)
| | - Charles F Lynch
- The Iowa Cancer Registry, The University of Iowa, Iowa City (Selk, Lynch)
| | - Thomas C Tucker
- The Kentucky Cancer Registry, University of Kentucky, Markey Cancer Center, Lexington (Tucker)
| | - Mary Anne Lynch
- The Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans (Lynch, Lefante, Wu)
| | - Christina Lefante
- The Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans (Lynch, Lefante, Wu)
| | - Xiao-Cheng Wu
- The Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans (Lynch, Lefante, Wu)
| | | | - Jennifer A Doherty
- The Utah Cancer Registry (Sweeney, Doherty)
- Huntsman Cancer Institute (Doherty), University of Utah, Salt Lake City
| | - Lynne S Penberthy
- The Surveillance Research Program, Division of Cancer Control and Population Sciences (Yuan, Van Dyke, Petkov, Hussey, Penberthy), National Cancer Institute, National Institutes of Health, Rockville, Maryland
| |
Collapse
|
24
|
Millar MM, Yoder V, Jozwik D, Espinoza J, Lemons D, Jewell CY, Sweeney C. Improving Central Cancer Registry Surveillance through Interstate Data Exchange of Electronic Pathology Reports. J Registry Manag 2021; 48:59-63. [PMID: 35380997 PMCID: PMC9009213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
When a cancer case is diagnosed or treated in one US state, but the patient resides in another, the case report abstract is shared with the central cancer registry in the state of residence through interstate data exchange. However, the records shared may not include pathology reports. Cases diagnosed in another state that would be ascertained only from pathology reports may thus be missed. Utah Cancer Registry received many electronic pathology (e-path) records for nonresident cases that were not being shared. In 2019, Utah Cancer Registry implemented workflow changes and created a novel data extract process to share e-path records in a North American Association of Central Cancer Registries (NAACCR) HL7 format. Utah Cancer Registry shared e-path records for an estimated 2,773 cases with other states for the diagnosis year 2018. Of these cases, both an e-path record and NAACCR-format abstract were shared for 1,709 (61.6%), whereas e-path record only was shared for 1,064 (38.4%). The largest number of e-path records went to 2 adjacent states: Idaho (n = 1,084) and Wyoming (n = 621). Receiving registries reported success importing the files. The e-path data stream resulted in ascertainment of 96 new cases for Idaho and 89 for Wyoming for diagnosis year 2018. Whereas most shared e-path records represented cases already known to the receiving registry, registry staff provided feedback that it was beneficial to obtain the additional documentation. Linking and reviewing the shared e-path records did represent additional workload. Central cancer registries can adopt this process for sharing e-path records via interstate data exchange to support complete case ascertainment in collaborating states.
Collapse
|
25
|
Niazi T, Williams S, Davis I, Stockler M, Martin A, Bracken K, Roncolato F, McJannett M, Horvath L, Sengupta S, Hughes S, McDermott R, Catto J, Kelly P, Vapiwala N, Parulekar W, Morgan S, Rendon R, Sweeney C. 694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
26
|
Pedregal Trujillo M, Ravi P, Shaw G, Markt S, Hamid A, Tewari A, Van Allen E, Sweeney C. 792P A retrospective review of the survival outcomes of patients with nonseminomatous germ cell tumors (NSGCTs) with and without teratoma in the primary. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
27
|
Gallicchio L, Elena JW, Fagan S, Carter M, Hamilton AS, Hastert TA, Hunter LL, Li J, Lynch CF, Milam J, Millar MM, Modjeski D, Paddock LE, Reed AR, Moses LB, Stroup AM, Sweeney C, Trapido EJ, West MM, Wu XC, Helzlsouer KJ. Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study. Cancer Epidemiol Biomarkers Prev 2020; 29:1699-1709. [PMID: 32651214 DOI: 10.1158/1055-9965.epi-20-0153] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 04/24/2020] [Accepted: 06/09/2020] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND While the primary role of central cancer registries in the United States is to provide vital information needed for cancer surveillance and control, these registries can also be leveraged for population-based epidemiologic studies of cancer survivors. This study was undertaken to assess the feasibility of using the NCI's Surveillance, Epidemiology, and End Results (SEER) Program registries to rapidly identify, recruit, and enroll individuals for survivor research studies and to assess their willingness to engage in a variety of research activities. METHODS In 2016 and 2017, six SEER registries recruited both recently diagnosed and longer-term survivors with early age-onset multiple myeloma or colorectal, breast, prostate, or ovarian cancer. Potential participants were asked to complete a survey, providing data on demographics, health, and their willingness to participate in various aspects of research studies. RESULTS Response rates across the registries ranged from 24.9% to 46.9%, with sample sizes of 115 to 239 enrolled by each registry over a 12- to 18-month period. Among the 992 total respondents, 90% answered that they would be willing to fill out a survey for a future research study, 91% reported that they would donate a biospecimen of some type, and approximately 82% reported that they would consent to have their medical records accessed for research. CONCLUSIONS This study demonstrated the feasibility of leveraging SEER registries to recruit a geographically and racially diverse group of cancer survivors. IMPACT Central cancer registries are a source of high-quality data that can be utilized to conduct population-based cancer survivor studies.
Collapse
Affiliation(s)
- Lisa Gallicchio
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland.
| | - Joanne W Elena
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland
| | - Sarah Fagan
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland
| | - Marjorie Carter
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah
| | - Ann S Hamilton
- Department of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, California
| | - Theresa A Hastert
- Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.,Population Studies and Disparities Research Program, Karmanos Cancer Institute, Detroit, Michigan
| | - Lisa L Hunter
- Iowa Cancer Registry, University of Iowa College of Public Health, Iowa City, Iowa
| | - Jie Li
- New Jersey State Cancer Registry, State of New Jersey, Department of Health, Trenton, New Jersey
| | - Charles F Lynch
- Iowa Cancer Registry, University of Iowa College of Public Health, Iowa City, Iowa.,Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa.,Cancer Epidemiology and Population Science Program, Holden Comprehensive Cancer Center, Iowa City, Iowa
| | - Joel Milam
- Department of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, California
| | - Morgan M Millar
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah.,Department of Internal Medicine, University of Utah, Salt Lake City, Utah
| | - Denise Modjeski
- Department of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, California
| | - Lisa E Paddock
- New Jersey State Cancer Registry, State of New Jersey, Department of Health, Trenton, New Jersey.,Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey.,Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| | - Amanda R Reed
- Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.,Population Studies and Disparities Research Program, Karmanos Cancer Institute, Detroit, Michigan
| | - Lisa B Moses
- Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans, Louisiana
| | - Antoinette M Stroup
- New Jersey State Cancer Registry, State of New Jersey, Department of Health, Trenton, New Jersey.,Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey.,Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
| | - Carol Sweeney
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah.,Department of Internal Medicine, University of Utah, Salt Lake City, Utah.,Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Edward J Trapido
- Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans, Louisiana.,Department of Epidemiology, Louisiana State University Health Sciences Center School of Public Health, New Orleans, Louisiana
| | - Michele M West
- Iowa Cancer Registry, University of Iowa College of Public Health, Iowa City, Iowa.,Cancer Epidemiology and Population Science Program, Holden Comprehensive Cancer Center, Iowa City, Iowa
| | - Xiao-Cheng Wu
- Louisiana Tumor Registry, Louisiana State University School of Public Health, New Orleans, Louisiana
| | - Kathy J Helzlsouer
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland
| |
Collapse
|
28
|
Gulbahce HE, White S, Herget KA, Stoddard G, Camp NJ, Buys SS, Sweeney C. 21-gene recurrence score testing utilization among older women from different races: A population-based study. J Geriatr Oncol 2020; 12:206-211. [PMID: 32646620 DOI: 10.1016/j.jgo.2020.06.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 03/13/2020] [Accepted: 06/03/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVES The influence of older age at diagnosis in combination with race/ethnicity on utilization and results of the 21-gene recurrence score (RS) assay for breast cancer (BC) patients is not fully understood. Our objectives were to evaluate the utilization of RS among older women with BC, the likelihood of a high-risk RS, and factors associated with breast cancer-specific mortality (BCSM) among older patients across different races. MATERIALS AND METHODS We utilized the Surveillance, Epidemiology, and Results (SEER) database with linked RS results to evaluate women with estrogen receptor-positive BC diagnosed 2004-2015. Multivariable logistic regression was used to describe the differences in utilization of RS testing and the association of high-risk RS according to patient characteristics. The Cox proportional hazards model was used to analyze factors associated with BCSM. RESULTS We found that 20.4% (109,244/536,555) of all women ≥18 and 14.3% (33,584/235,171) of women ≥65 underwent RS testing. Non-whites had lower odds of RS testing at younger ages whereas among women ≥65 there was no significant difference. After taking into account stage and grade, being ≥65 reduced the odds of high-risk RS in all races except American Indian/Alaskan Native. Age ≥ 65 was independently associated with increased hazard BCSM. Among women ≥65 with high-risk RS, chemotherapy was associated with lower hazard of BCSM in all races. CONCLUSIONS Older women are less likely to be tested for RS, but also less likely to have high-risk RS. Older women with high-risk RS, when given chemotherapy have reduced BCSM across all races.
Collapse
Affiliation(s)
- H Evin Gulbahce
- Department of Pathology, Huntsman Cancer Institute, University of Utah Health, 2000 Circle of Hope, Room 3100, Salt Lake City, UT 84112, United States of America.
| | - Sandra White
- Department of Pathology, Huntsman Cancer Institute, University of Utah Health, 2000 Circle of Hope, Room 3100, Salt Lake City, UT 84112, United States of America.
| | - Kimberly A Herget
- Utah Cancer Registry, 250 East 200 South, Room 1375, Salt Lake City, UT 84111, United States of America.
| | - Greg Stoddard
- Department of Internal Medicine, Division of Epidemiology, University of Utah Health, 295 Chipeta Building, Salt Lake City, UT 84108, United States of America.
| | - Nicola J Camp
- Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah Health, 2000 Circle of Hope, Suite 4126, Salt Lake City, UT 84112, United States of America.
| | - Saundra S Buys
- Department of Internal Medicine, Division of Oncology, University of Utah Health, 1950 Circle of Hope, Salt Lake City, UT 84103, United States of America.
| | - Carol Sweeney
- Utah Cancer Registry, 250 East 200 South, Room 1375, Salt Lake City, UT 84111, United States of America; Department of Internal Medicine, Division of Epidemiology, University of Utah Health, 295 Chipeta Building, Salt Lake City, UT 84108, United States of America.
| |
Collapse
|
29
|
Hashibe M, Ou JY, Herget K, Bolton D, McPherson J, Hawley C, Garvin J, Doherty JA, Sweeney C. Feasibility of Capturing Cancer Treatment Data in the Utah All-Payer Claims Database. JCO Clin Cancer Inform 2020; 3:1-10. [PMID: 31756128 DOI: 10.1200/cci.19.00027] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
PURPOSE Incompleteness of treatment data is a recognized limitation of cancer registry data. An all-payer claims database (APCD) is a tool that states use to capture health care information across systems and payer. We linked the Utah Cancer Registry (UCR) records to Utah's statewide APCD and evaluated how this linkage led to improvements in the capture of cancer treatment information. METHODS We linked cancers diagnosed and reported to the UCR with Utah APCD claims for the calendar years 2013 and 2014 using LinkPlus Software. For patients with breast or colorectal cancers, manual abstraction was completed to provide a gold-standard comparison for the treatment data obtained from the claims. RESULTS Among 10,759 reportable cancer occurrences linked to the APCD, the claims identified additional patients with cancer who received therapies that had been unknown to the registry, increasing the proportion treated with chemotherapy from 23.7% to 27.6%, hormone therapy from 14.1% to 18.8%, immunotherapy from 4.3% to 13.2%, and radiation therapy from 24.9% to 27.5%. The APCD increased the sensitivity of treatment variables compared with the abstraction gold standard. Notably, sensitivity of hormonal therapy for breast cancer increased from 78.6% to 95.2% when augmented with APCD claims data. However, the APCD alone did not achieve as high specificity for treatment data as did the data collected through traditional registry methods. CONCLUSIONS This is the first study, to our knowledge, showing that linking cancer registry data with a statewide claims database that covers multiple insurance companies improves cancer treatment data collection. Linking of cancer registry and APCD data can improve comprehensiveness of cancer registry treatment data.
Collapse
Affiliation(s)
- Mia Hashibe
- Utah Cancer Registry, University of Utah, Salt Lake City, UT.,University of Utah School of Medicine, Salt Lake City, UT
| | - Judy Y Ou
- Utah Cancer Registry, University of Utah, Salt Lake City, UT.,University of Utah School of Medicine, Salt Lake City, UT
| | - Kimberly Herget
- Utah Cancer Registry, University of Utah, Salt Lake City, UT
| | - Dan Bolton
- University of Utah School of Medicine, Salt Lake City, UT
| | | | | | | | - Jennifer A Doherty
- Utah Cancer Registry, University of Utah, Salt Lake City, UT.,University of Utah School of Medicine, Salt Lake City, UT
| | - Carol Sweeney
- Utah Cancer Registry, University of Utah, Salt Lake City, UT.,University of Utah School of Medicine, Salt Lake City, UT
| |
Collapse
|
30
|
Hanson HA, Leiser CL, Madsen MJ, Gardner J, Knight S, Cessna M, Sweeney C, Doherty JA, Smith KR, Bernard PS, Camp NJ. Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The Power of the Utah Population Database. Cancer Epidemiol Biomarkers Prev 2020; 29:807-815. [PMID: 32098891 PMCID: PMC7168701 DOI: 10.1158/1055-9965.epi-19-0912] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 01/15/2020] [Accepted: 02/18/2020] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Previously, family-based designs and high-risk pedigrees have illustrated value for the discovery of high- and intermediate-risk germline breast cancer susceptibility genes. However, genetic heterogeneity is a major obstacle hindering progress. New strategies and analytic approaches will be necessary to make further advances. One opportunity with the potential to address heterogeneity via improved characterization of disease is the growing availability of multisource databases. Specific to advances involving family-based designs are resources that include family structure, such as the Utah Population Database (UPDB). To illustrate the broad utility and potential power of multisource databases, we describe two different novel family-based approaches to reduce heterogeneity in the UPDB. METHODS Our first approach focuses on using pedigree-informed breast tumor phenotypes in gene mapping. Our second approach focuses on the identification of families with similar pleiotropies. We use a novel network-inspired clustering technique to explore multi-cancer signatures for high-risk breast cancer families. RESULTS Our first approach identifies a genome-wide significant breast cancer locus at 2q13 [P = 1.6 × 10-8, logarithm of the odds (LOD) equivalent 6.64]. In the region, IL1A and IL1B are of particular interest, key cytokine genes involved in inflammation. Our second approach identifies five multi-cancer risk patterns. These clusters include expected coaggregations (such as breast cancer with prostate cancer, ovarian cancer, and melanoma), and also identify novel patterns, including coaggregation with uterine, thyroid, and bladder cancers. CONCLUSIONS Our results suggest pedigree-informed tumor phenotypes can map genes for breast cancer, and that various different cancer pleiotropies exist for high-risk breast cancer pedigrees. IMPACT Both methods illustrate the potential for decreasing etiologic heterogeneity that large, population-based multisource databases can provide.See all articles in this CEBP Focus section, "Modernizing Population Science."
Collapse
Affiliation(s)
- Heidi A Hanson
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
- Utah Population Database, University of Utah, Salt Lake City, Utah
- Department of Surgery, University of Utah, Salt Lake City, Utah
| | - Claire L Leiser
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- Department of Epidemiology, University of Washington, Seattle, Washington
| | - Michael J Madsen
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - John Gardner
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | | | - Melissa Cessna
- Intermountain Biorepository, Intermountain Healthcare, Salt Lake City, Utah
- Department of Pathology, Intermountain Medical Center, Intermountain Healthcare, Salt Lake City, Utah
| | - Carol Sweeney
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah
- Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah
| | - Jennifer A Doherty
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah
- Department of Population Sciences, University of Utah School of Medicine, Salt Lake City, Utah
| | - Ken R Smith
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- Utah Population Database, University of Utah, Salt Lake City, Utah
- Department of Family and Consumer Studies, University of Utah, Salt Lake City, Utah
| | - Philip S Bernard
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- Department of Pathology, University of Utah, Salt Lake City, Utah
| | - Nicola J Camp
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- Utah Population Database, University of Utah, Salt Lake City, Utah
- Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah
| |
Collapse
|
31
|
Gulbahce E, White S, Stoddard GJ, Herget K, Sweeney C. Abstract P2-08-15: 21-gene recurrence score testing utilization among older women from different races: A surveillance, epidemiology and end results (SEER) study. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p2-08-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: About 50% of breast cancers (BrCa) occur in women over the age of 65. Although chemotherapy improves survival in patients with estrogen receptor (ER) positive BrCa, benefits of chemotherapy in older woman must be weighed against the risks of morbidity associated with chemotherapy and non-BrCa associated mortality at older ages. OncotyeDX, 21-gene Recurrence Score (RS) identifies patients who may benefit from chemotherapy. In this study we looked at utilization of RS testing and likelihood of high-risk RS score in the older population across different races. Materials and Methods: We used Surveillance Epidemiology and End Result (SEER) data, linked to RS scores by the SEER program, to identify women older than 18 diagnosed with ER positive BrCa between the years 2004 and 2015. Patients with Stage 4 disease and T4 tumors were excluded. Patients were stratified into low (RS <11), intermediate (RS 11-25), and high-risk (RS>25) groups following TAILORx trial cut offs. Multivariable logistic regression model was used to identify factors associated with utilization of RS testing and association with high-risk RS. Results: Of 539,693 patients older than 18 years of age with ER positive, stage I-III BrCa identified between 2004 and 2015 in SEER registries, 109,835 (20.35%) had RS testing performed. The odds of having RS testing done was lower among women ≥65 compared to younger women in all races. The characteristics that increased odds of testing included progesterone receptor positive tumors, later years of diagnosis (2010-2015 compared to 2004-2009), negative nodes, T1 tumors, and Grade 1-2 (compared to Grade 3) tumors, were largely consistent across race groups. Blacks and American Indian/Alaskan Natives had higher odds of high-risk RS compared to non-Hispanic whites, after adjusting for stage, grade, and age. Being age 65 and older reduced the odds of having high-risk RS by odds ratio (OR) 0.58 in non-Hispanic whites, adjusted for progesterone receptor status, tumor size, positive nodes, and grade. The reduced odds of high-risk RS associated with being age 65 and older was more pronounced among black women, adjusted OR 0.44 (0.37 - 0.51) and among Asian or Pacific Islander women OR 0.44 (0.37 - 0.51). Conclusion: Older women of all races are less likely to be tested for 21-gene RS. Among women who were tested, those age 65 and older were less likely to have high-risk RS result. Blacks and American Indian/Alaskan Natives have higher risk of having high-risk RS after controlling for stage, age and other clinical and pathologic predictors.
Citation Format: Evin Gulbahce, Sandra White, Gregory J Stoddard, Kim Herget, Carol Sweeney. 21-gene recurrence score testing utilization among older women from different races: A surveillance, epidemiology and end results (SEER) study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-15.
Collapse
|
32
|
Wei M, Pappas L, Guinto E, Sweeney C, Camp N, Freer P, Buys S, Henry NL, Curtin K. Abstract P2-08-10: Mammographic breast density changes with endocrine therapy (ET) in women with hormone receptor positive (HR+) breast cancer in a Utah population. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p2-08-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Women with extremely dense breast tissue on mammography have a higher risk of breast cancer compared to similarly-aged women with less dense breast tissue. Tamoxifen therapy has been observed to reduce breast density among both pre- and postmenopausal women with HR+ breast cancer and may predict benefit of therapy. Studies of aromatase inhibitor (AI) therapy and breast density change, however, are limited and results inconclusive. Factors associated with breast density change with ET, and effect of duration of ET on breast density change, have not been well studied.
Methods: Using the Utah Population Database, women were identified who underwent screening mammography in 2005-2016 and who had no personal history of breast cancer. Those who were subsequently diagnosed with HR+ breast cancer and treated in one of the major health care systems in Utah (Intermountain Healthcare or University of Utah Health) were included in the analysis. ET prescription information and duration of ET were obtained from provider records and the Utah All-Payer Claims Database. Women with mammography results in the electronic medical record both before and within 3 years after the breast cancer diagnosis were included. BI-RADS density classification from mammogram reports 6-12 months, 13-24 months, and 25-36 months after ET initiation were compared to pre-diagnosis BI-RADS density classification. Breast density reduction was defined as a decrease of ≥1 BI-RADS category compared to baseline. Fisher’s exact test was used to examine ET and breast density reduction among women ≥55y and <55y.
Results: In total, 1328 women with HR+ breast cancer and baseline BI-RADS breast density categories B-D were included. Women with BI-RADS density category A(almost entirely fatty) were excluded. A majority (61%) were age ≥55y at diagnosis, were non-Hispanic white (90%), and had BMI ≥25 kg/m2 (56%); 15% had a first-degree family history of breast cancer. At baseline, 602 (44%) women had scattered fibroglandular densities (BI-RADS category B), 697 (50%) had heterogeneously dense breasts (BI-RADS category C), and 83 (6%) had extremely dense breasts (BI-RADS category D). Half were treated with AI only (49%), 21% with tamoxifen only, and 29% with both during follow-up. In both the age ≥55y and <55y groups, women with BI-RADS category D at baseline were more likely to experience a reduction in breast density with ET compared to women with either BI-RADS categories B or C (Table 1). There were no significant differences in breast density reduction observed between women treated with AI only compared to those treated with tamoxifen only, irrespective of age and baseline density. Breast cancer family history also had no effect on breast density reduction with ET.
Conclusion: Baseline breast density is associated with a demonstrable reduction in breast density during ET. Our findings suggest that AI therapy can reduce breast density similar to that seen with tamoxifen therapy.
Table 1 Breast Density (BD) changes among women who underwent mammography 6-12 months, 13-24 months, and 25-36 months after ET initiationBaseline BDN≥55 years oldPTotal<55 years oldPNo BD reduction N(%)BD reduction N(%)No BD reduction N(%)BD reduction N(%)6-12 months after ET initiationScattered157152(97)5(3)5452(96)2(3)Heterogeneous148115(78)33(22)10477(74)27(26)Dense144(29)10(71)<0.0001248(33)16(67)<0.0001Total319271(85)48(15)182137 (75)45(25)13-24 months after ET initiationScattered232214(92)18(8)8473(87)11(13)Heterogeneous211144(68)67(32)155107(69)48(31)Dense172(12)15(88)<0.0001287(25)21(75)<0.0001Total460360(78)100(22)267187(70)80(30)25-36 months after ET initiationScattered248220(89)28(11)8374(89)9 (11)Heterogeneous203133(66)70(35)16097(61)63(39)Dense162(13)14(88)<0.00013213(41)19 (59)<0.0001Total467355(76)112(24)275184(67)91(33)
Citation Format: Mei Wei, Lisa Pappas, Emily Guinto, Carol Sweeney, Nicola Camp, Phoebe Freer, Saundra Buys, N. Lynn Henry, Karen Curtin. Mammographic breast density changes with endocrine therapy (ET) in women with hormone receptor positive (HR+) breast cancer in a Utah population [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-10.
Collapse
Affiliation(s)
- Mei Wei
- 1Huntsman Cancer Institute, Salt Lake City, UT
| | - Lisa Pappas
- 1Huntsman Cancer Institute, Salt Lake City, UT
| | | | | | - Nicola Camp
- 1Huntsman Cancer Institute, Salt Lake City, UT
| | | | | | | | | |
Collapse
|
33
|
Millar MM, Elena JW, Gallicchio L, Edwards SL, Carter ME, Herget KA, Sweeney C. The feasibility of web surveys for obtaining patient-reported outcomes from cancer survivors: a randomized experiment comparing survey modes and brochure enclosures. BMC Med Res Methodol 2019; 19:208. [PMID: 31730474 PMCID: PMC6858678 DOI: 10.1186/s12874-019-0859-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Accepted: 10/23/2019] [Indexed: 11/30/2022] Open
Abstract
Background Central cancer registries are often used to survey population-based samples of cancer survivors. These surveys are typically administered via paper or telephone. In most populations, web surveys obtain much lower response rates than paper surveys. This study assessed the feasibility of web surveys for collecting patient-reported outcomes via a central cancer registry. Methods Potential participants were sampled from Utah Cancer Registry records. Sample members were randomly assigned to receive a web or paper survey, and then randomized to either receive or not receive an informative brochure describing the cancer registry. We calculated adjusted risk ratios with 95% confidence intervals to compare response likelihood and the demographic profile of respondents across study arms. Results The web survey response rate (43.2%) was lower than the paper survey (50.4%), but this difference was not statistically significant (adjusted risk ratio = 0.88, 95% confidence interval = 0.72, 1.07). The brochure also did not significantly influence the proportion responding (adjusted risk ratio = 1.03, 95% confidence interval = 0.85, 1.25). There were few differences in the demographic profiles of respondents across the survey modes. Older age increased likelihood of response to a paper questionnaire but not a web questionnaire. Conclusions Web surveys of cancer survivors are feasible without significantly influencing response rates, but providing a paper response option may be advisable particularly when surveying older individuals. Further examination of the varying effects of brochure enclosures across different survey modes is warranted.
Collapse
Affiliation(s)
- Morgan M Millar
- Department of Internal Medicine, 295 Chipeta Way University of Utah, Salt Lake City, UT, 84132, USA. .,Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA.
| | - Joanne W Elena
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20852, USA
| | - Lisa Gallicchio
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20852, USA
| | - Sandra L Edwards
- Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA
| | - Marjorie E Carter
- Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA
| | - Kimberly A Herget
- Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA
| | - Carol Sweeney
- Department of Internal Medicine, 295 Chipeta Way University of Utah, Salt Lake City, UT, 84132, USA.,Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA.,Huntsman Cancer Institute, University of Utah, 2000 Cir of Hope Dr. Salt, Lake City, UT, 84112, USA
| |
Collapse
|
34
|
Millar MM, Elena JW, Gallicchio L, Edwards SL, Carter ME, Herget KA, Sweeney C. The feasibility of web surveys for obtaining patient-reported outcomes from cancer survivors: a randomized experiment comparing survey modes and brochure enclosures. BMC Med Res Methodol 2019. [PMID: 31730474 DOI: 10.1186/s12874-019-0859-9:10.1186/s12874-019-0859-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
Abstract
BACKGROUND Central cancer registries are often used to survey population-based samples of cancer survivors. These surveys are typically administered via paper or telephone. In most populations, web surveys obtain much lower response rates than paper surveys. This study assessed the feasibility of web surveys for collecting patient-reported outcomes via a central cancer registry. METHODS Potential participants were sampled from Utah Cancer Registry records. Sample members were randomly assigned to receive a web or paper survey, and then randomized to either receive or not receive an informative brochure describing the cancer registry. We calculated adjusted risk ratios with 95% confidence intervals to compare response likelihood and the demographic profile of respondents across study arms. RESULTS The web survey response rate (43.2%) was lower than the paper survey (50.4%), but this difference was not statistically significant (adjusted risk ratio = 0.88, 95% confidence interval = 0.72, 1.07). The brochure also did not significantly influence the proportion responding (adjusted risk ratio = 1.03, 95% confidence interval = 0.85, 1.25). There were few differences in the demographic profiles of respondents across the survey modes. Older age increased likelihood of response to a paper questionnaire but not a web questionnaire. CONCLUSIONS Web surveys of cancer survivors are feasible without significantly influencing response rates, but providing a paper response option may be advisable particularly when surveying older individuals. Further examination of the varying effects of brochure enclosures across different survey modes is warranted.
Collapse
Affiliation(s)
- Morgan M Millar
- Department of Internal Medicine, 295 Chipeta Way University of Utah, Salt Lake City, UT, 84132, USA. .,Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA.
| | - Joanne W Elena
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20852, USA
| | - Lisa Gallicchio
- Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD, 20852, USA
| | - Sandra L Edwards
- Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA
| | - Marjorie E Carter
- Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA
| | - Kimberly A Herget
- Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA
| | - Carol Sweeney
- Department of Internal Medicine, 295 Chipeta Way University of Utah, Salt Lake City, UT, 84132, USA.,Utah Cancer Registry, University of Utah, 250 E 200 S, Suite 1375, Salt Lake City, UT, 84111, USA.,Huntsman Cancer Institute, University of Utah, 2000 Cir of Hope Dr. Salt, Lake City, UT, 84112, USA
| |
Collapse
|
35
|
Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A, Hafen B, Herget KA, Kohlmann W, Roundy C, Sweeney C. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med 2019; 8:6789-6798. [PMID: 31531966 PMCID: PMC6825998 DOI: 10.1002/cam4.2534] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 08/13/2019] [Accepted: 08/14/2019] [Indexed: 12/21/2022] Open
Abstract
Background Personal cancer diagnosis and family cancer history factor into which individuals should undergo genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome. Family history is often determined in the research setting through kindreds with disease clusters, or clinically from self‐report. The population prevalence of individuals with diagnostic characteristics and/or family cancer history meeting criteria for HBOC testing is unknown. Methods Utilizing Surveillance, Epidemiology, and End Results (SEER) cancer registry data and a research resource linking registry records to genealogies, the Utah Population Database, the population‐based prevalence of diagnostic and family history characteristics meeting National Comprehensive Cancer Network (NCCN) criteria for HBOC testing was objectively assessed. Results Among Utah residents with an incident breast cancer diagnosis 2010‐2015 and evaluable for family history, 21.6% met criteria for testing based on diagnostic characteristics, but the proportion increased to 62.9% when family history was evaluated. The proportion of cases meeting testing criteria at diagnosis was 94% for ovarian cancer, 23% for prostate cancer, and 51.1% for pancreatic cancer. Among an unaffected Utah population of approximately 1.7 million evaluable for family history, 197,601 or 11.6% met testing criteria based on family history. Conclusions This study quantifies the population‐based prevalence of HBOC criteria using objectively determined genealogy and cancer incidence data. Sporadic breast cancer likely represents a portion of the high prevalence of family cancer history seen in this study. These results underline the importance of establishing presence of a deleterious mutation in an affected family member, per NCCN guidelines, before testing unaffected relatives.
Collapse
Affiliation(s)
| | - Saundra S Buys
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,Department of Internal Medicine, University of Utah, Salt Lake City, Utah
| | | | - Whitney Espinel
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Alison Fraser
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Amanda Gammon
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Brent Hafen
- Intermountain Healthcare, Salt Lake City, Utah
| | | | - Wendy Kohlmann
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | | | - Carol Sweeney
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,Department of Internal Medicine, University of Utah, Salt Lake City, Utah.,Utah Cancer Registry, University of Utah, Salt Lake City, Utah
| |
Collapse
|
36
|
Prast‐Nielsen S, Tobin A, Adamzik K, Powles A, Hugerth L, Sweeney C, Kirby B, Engstrand L, Fry L. 皮肤微生物组检查. Br J Dermatol 2019. [DOI: 10.1111/bjd.18291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Azgahdi S, Candas D, Xie B, Zhang L, Zhang Y, Fan M, Liu L, Sweeney C, Pan C, Ozpiskin O, Vaughan A, Wang J, Xia S, Monjazeb A, Woloschak G, Grdina D, Murphy W, Sun L, Chen H, Lam K, Weichselbaum R, Li J. Dual Blockade of CD47 and HER2 Re-sensitizes Resistant Breast Cancer Cells to Radiation Therapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Prast‐Nielsen S, Tobin A, Adamzik K, Powles A, Hugerth L, Sweeney C, Kirby B, Engstrand L, Fry L. Investigation of the skin microbiome. Br J Dermatol 2019. [DOI: 10.1111/bjd.18279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
39
|
Prast-Nielsen S, Tobin AM, Adamzik K, Powles A, Hugerth LW, Sweeney C, Kirby B, Engstrand L, Fry L. Investigation of the skin microbiome: swabs vs. biopsies. Br J Dermatol 2019; 181:572-579. [PMID: 30693476 DOI: 10.1111/bjd.17691] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/21/2019] [Indexed: 12/27/2022]
Abstract
BACKGROUND Human skin is populated by diverse bacteria and there is increasing evidence that resident bacteria play a key role initiating immune responses in cutaneous diseases such as atopic dermatitis, psoriasis and hidradenitis suppurativa. Bacteria are present at all layers of the skin but many studies have relied on swabs to profile the skin microbiota. OBJECTIVES As the pathogenesis of many skin conditions is dermal, we wanted to compare the microbiota obtained in swabs (surface) and biopsies (dermis). METHODS Using 16S rRNA gene sequencing we established the microbial profiles of skin swabs and skin biopsies in 16 patients. RESULTS We found differences in both diversity and taxonomic composition of the microbiome obtained from swabs and biopsies of the same individual. Several taxa were found to be more abundant in the swabs, which displayed significantly higher community richness, but Clostridiales and Bacteroidetes were significantly enriched in the biopsies. Most published research on cutaneous microbiota has been based on skin swabs, which represent the surface of the skin. CONCLUSIONS Our study demonstrated a clear difference between the microbiome observed from skin swabs and skin biopsies. These findings may be highly relevant in disorders such as psoriasis where pathogenesis arises in the dermis. What's already known about this topic? 16S RNA gene sequencing has facilitated study of the skin microbiome. Several studies have sequenced the microbiome sampled by skin swabs. What does this study add? The microbiome data obtained using swabs and biopsies were different. Diseases that are predominantly dermal should be studied using both swabs and biopsies.
Collapse
Affiliation(s)
- S Prast-Nielsen
- Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden.,Centre for Translational Microbiome Research (CTMR), Karolinska Institute, Stockholm, Sweden
| | - A-M Tobin
- Centre for Translational Microbiome Research (CTMR), Karolinska Institute, Stockholm, Sweden.,Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland
| | - K Adamzik
- Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland
| | | | - L W Hugerth
- Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden.,Centre for Translational Microbiome Research (CTMR), Karolinska Institute, Stockholm, Sweden
| | - C Sweeney
- Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland
| | - B Kirby
- Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland
| | - L Engstrand
- Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden.,Centre for Translational Microbiome Research (CTMR), Karolinska Institute, Stockholm, Sweden
| | - L Fry
- Imperial College, London, U.K
| |
Collapse
|
40
|
Millar MM, Kinney AY, Camp NJ, Cannon-Albright LA, Hashibe M, Penson DF, Kirchhoff AC, Neklason DW, Gilsenan AW, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME, Sweeney C. Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies. Am J Epidemiol 2019. [PMID: 30689685 DOI: 10.1093/aje/kwz011:10.1093/aje/kwz011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
Abstract
When recruiting research participants through central cancer registries, high response fractions help ensure population-based representation. We conducted multivariable mixed-effects logistic regression to identify case and study characteristics associated with making contact with and obtaining cooperation of Utah cancer cases using data from 17 unique recruitment efforts undertaken by the Utah Cancer Registry (2007-2016) on behalf of the following studies: A Population-Based Childhood Cancer Survivors Cohort Study in Utah, Comparative Effectiveness Analysis of Surgery and Radiation for Prostate Cancer (CEASAR Study), Costs and Benefits of Follow-up Care for Adolescent and Young Adult Cancers, Study of Exome Sequencing for Head and Neck Cancer Susceptibility Genes, Genetic Epidemiology of Chronic Lymphocytic Leukemia, Impact of Remote Familial Colorectal Cancer Risk Assessment and Counseling (Family CARE Project), Massively Parallel Sequencing for Familial Colon Cancer Genes, Medullary Thyroid Carcinoma (MTC) Surveillance Study, Osteosarcoma Surveillance Study, Prostate Cancer Outcomes Study, Risk Education and Assessment for Cancer Heredity Project (REACH Project), Study of Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk Breast-Cancer Gene Pedigrees, Study of Shared Genomic Segment Analysis for Localizing Multiple Myeloma Genes. Characteristics associated with lower odds of contact included Hispanic ethnicity (odds ratio (OR) = 0.34, 95% confidence interval (CI): 0.27, 0.41), nonwhite race (OR = 0.46, 95% CI: 0.35, 0.60), and younger age at contact. Years since diagnosis was inversely associated with making contact. Nonwhite race and age ≥60 years had lower odds of cooperation. Study features with lower odds of cooperation included longitudinal design (OR = 0.50, 95% CI: 0.41, 0.61) and study brochures (OR = 0.70, 95% CI: 0.54, 0.90). Increased odds of cooperation were associated with including a questionnaire (OR = 3.19, 95% CI: 1.54, 6.59), postage stamps (OR = 1.60, 95% CI: 1.21, 2.12), and incentives (OR = 1.62, 95% CI: 1.02, 2.57). Among cases not responding after the first contact, odds of eventual response were lower when >10 days elapsed before subsequent contact (OR = 0.71, 95% CI: 0.59, 0.85). Obtaining high response is challenging, but study features identified in this analysis support better results when recruiting through central cancer registries.
Collapse
Affiliation(s)
- Morgan M Millar
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah.,Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Anita Y Kinney
- Department of Biostatistics and Epidemiology, School of Public Health, Rutgers University, New Brunswick, New Jersey.,Rutgers Cancer Institute of New Jersey, Rutgers Health, Rutgers University, New Brunswick, New Jersey
| | - Nicola J Camp
- Division of Hematology and Hematological Malignancies, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah.,Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Lisa A Cannon-Albright
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah.,Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Mia Hashibe
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah.,Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah.,Division of Public Health, Department of Family and Preventive Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
| | - David F Penson
- Urologic Surgery, Department of Urology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee.,Center for Surgical Quality and Outcomes Research, Vanderbilt Institute for Medicine and Public Health, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee
| | - Anne C Kirchhoff
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah.,Division of Pediatric Hematology and Oncology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah
| | - Deborah W Neklason
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah.,Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Alicia W Gilsenan
- Department of Epidemiology, RTI Health Solutions, RTI International, Research Triangle Park, North Carolina
| | - Gretchen S Dieck
- Safety, Epidemiology, and Risk Management, United BioSource Corporation, Blue Bell, Pennsylvania
| | - Antoinette M Stroup
- Rutgers Cancer Institute of New Jersey, Rutgers Health, Rutgers University, New Brunswick, New Jersey.,Division of Cancer Epidemiology, Rutgers School of Public Health, Rutgers University, New Brunswick, New Jersey.,New Jersey State Cancer Registry, New Jersey Department of Health, Trenton, New Jersey
| | - Sandra L Edwards
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Carrie Bateman
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Marjorie E Carter
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Carol Sweeney
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah.,Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah.,Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| |
Collapse
|
41
|
Millar MM, Kinney AY, Camp NJ, Cannon-Albright LA, Hashibe M, Penson DF, Kirchhoff AC, Neklason DW, Gilsenan AW, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME, Sweeney C. Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies. Am J Epidemiol 2019; 188:928-939. [PMID: 30689685 DOI: 10.1093/aje/kwz011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Revised: 01/09/2019] [Accepted: 01/10/2019] [Indexed: 12/24/2022] Open
Abstract
When recruiting research participants through central cancer registries, high response fractions help ensure population-based representation. We conducted multivariable mixed-effects logistic regression to identify case and study characteristics associated with making contact with and obtaining cooperation of Utah cancer cases using data from 17 unique recruitment efforts undertaken by the Utah Cancer Registry (2007-2016) on behalf of the following studies: A Population-Based Childhood Cancer Survivors Cohort Study in Utah, Comparative Effectiveness Analysis of Surgery and Radiation for Prostate Cancer (CEASAR Study), Costs and Benefits of Follow-up Care for Adolescent and Young Adult Cancers, Study of Exome Sequencing for Head and Neck Cancer Susceptibility Genes, Genetic Epidemiology of Chronic Lymphocytic Leukemia, Impact of Remote Familial Colorectal Cancer Risk Assessment and Counseling (Family CARE Project), Massively Parallel Sequencing for Familial Colon Cancer Genes, Medullary Thyroid Carcinoma (MTC) Surveillance Study, Osteosarcoma Surveillance Study, Prostate Cancer Outcomes Study, Risk Education and Assessment for Cancer Heredity Project (REACH Project), Study of Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk Breast-Cancer Gene Pedigrees, Study of Shared Genomic Segment Analysis for Localizing Multiple Myeloma Genes. Characteristics associated with lower odds of contact included Hispanic ethnicity (odds ratio (OR) = 0.34, 95% confidence interval (CI): 0.27, 0.41), nonwhite race (OR = 0.46, 95% CI: 0.35, 0.60), and younger age at contact. Years since diagnosis was inversely associated with making contact. Nonwhite race and age ≥60 years had lower odds of cooperation. Study features with lower odds of cooperation included longitudinal design (OR = 0.50, 95% CI: 0.41, 0.61) and study brochures (OR = 0.70, 95% CI: 0.54, 0.90). Increased odds of cooperation were associated with including a questionnaire (OR = 3.19, 95% CI: 1.54, 6.59), postage stamps (OR = 1.60, 95% CI: 1.21, 2.12), and incentives (OR = 1.62, 95% CI: 1.02, 2.57). Among cases not responding after the first contact, odds of eventual response were lower when >10 days elapsed before subsequent contact (OR = 0.71, 95% CI: 0.59, 0.85). Obtaining high response is challenging, but study features identified in this analysis support better results when recruiting through central cancer registries.
Collapse
Affiliation(s)
- Morgan M Millar
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Anita Y Kinney
- Department of Biostatistics and Epidemiology, School of Public Health, Rutgers University, New Brunswick, New Jersey
- Rutgers Cancer Institute of New Jersey, Rutgers Health, Rutgers University, New Brunswick, New Jersey
| | - Nicola J Camp
- Division of Hematology and Hematological Malignancies, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Lisa A Cannon-Albright
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Mia Hashibe
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
- Division of Public Health, Department of Family and Preventive Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
| | - David F Penson
- Urologic Surgery, Department of Urology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee
- Center for Surgical Quality and Outcomes Research, Vanderbilt Institute for Medicine and Public Health, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee
| | - Anne C Kirchhoff
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, Utah
| | - Deborah W Neklason
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Alicia W Gilsenan
- Department of Epidemiology, RTI Health Solutions, RTI International, Research Triangle Park, North Carolina
| | - Gretchen S Dieck
- Safety, Epidemiology, and Risk Management, United BioSource Corporation, Blue Bell, Pennsylvania
| | - Antoinette M Stroup
- Rutgers Cancer Institute of New Jersey, Rutgers Health, Rutgers University, New Brunswick, New Jersey
- Division of Cancer Epidemiology, Rutgers School of Public Health, Rutgers University, New Brunswick, New Jersey
- New Jersey State Cancer Registry, New Jersey Department of Health, Trenton, New Jersey
| | - Sandra L Edwards
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Carrie Bateman
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Marjorie E Carter
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
| | - Carol Sweeney
- Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
- Utah Cancer Registry, University of Utah Health, University of Utah, Salt Lake City, Utah
- Cancer Control and Population Sciences Program, Huntsman Cancer Institute, University of Utah Health, University of Utah, Salt Lake City, Utah
| |
Collapse
|
42
|
Thota R, Herget K, Sause WT, Curtin K, Sweeney C, Neklason DW. Epidemiological trends of small bowel tumors and changing incidence in Utah. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.4_suppl.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
245 Background: The incidence and prevalence of small bowel tumors in particular adenocarcinomas are thought to be rising but updated epidemiological data is lacking. Therefore, in this study we explored the evolving epidemiology of small bowel tumors. Methods: This is a retrospective population based study using Utah Cancer Registry (UCR) and Surveillance Epidemiology, and End Results program (SEER) conducted between 1973-2015. The age adjusted incidence and prevalence was determined. The incidence and prevalence rates were compared to other SEER residents diagnosed with invasive small bowel tumors using ICD codes C17.0 – C17.9). Results: The small bowel tumors have steadily increased from 1990 to 2015. In the UCR, the highest incidence of and small bowel tumors was reported 1.7 per 100,000 in 2015. The prevalence of small bowel tumors in the state of Utah from 1973 – 2014 was 616 including 41 adenocarcinomas, 327 with carcinoid tumors and 248 with other histology’s. There was 1.67% increase in incidence of small bowel tumors in SEER while in Utah we noted 2.81 % annual increase of incidence from 1990 to 2015. Especially, for small bowel adenocarcinomas, Utah has an annual increase of 2.43% from 1990-2015, and SEER had a smaller increase of 0.71% per year over the same time frame. Conclusions: The incidence of small bowel adenocarcinomas between 1995 and 2015 show a steady increase in both UCR and SEER databases. Despite the rarity of these tumors rising incidence warrants increasing awareness and need for better treatments to improve the survival outcomes of these under-studied tumors.
Collapse
Affiliation(s)
| | - Kim Herget
- Utah Cancer Registry, University of Utah, Salt Lake City, UT
| | | | - Karen Curtin
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
| | | | | |
Collapse
|
43
|
Garvin JH, Herget KA, Hashibe M, Kirchhoff AC, Hawley CW, Bolton D, Sweeney C. Linkage between Utah All Payers Claims Database and Central Cancer Registry. Health Serv Res 2019; 54:707-713. [PMID: 30675913 DOI: 10.1111/1475-6773.13114] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
OBJECTIVE To evaluate the linkage of claims from the Utah All Payers Claims Database (APCD) and Utah Cancer Registry (UCR). DATA SOURCES Secondary data from 2013 and 2014 Utah APCD and 2013 UCR cases. STUDY DESIGN This is a descriptive analysis of the quality of linkage between APCD claims data and cancer registry cases. DATA COLLECTION/EXTRACTION METHODS We used the LinkPlus software to link Utah APCD and UCR data. PRINCIPAL FINDINGS We were able to link 82.4 percent (9441/11 453) of the UCR reportable cancer cases with APCD claims. Of those linked, 66 percent were perfect matches. CONCLUSIONS The quality of identifiers is high, evidence that claims data can potentially supplement cancer registry data for use in research.
Collapse
Affiliation(s)
- Jennifer Hornung Garvin
- Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah.,Utah Cancer Registry, University of Utah, Salt Lake City, Utah.,Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.,Health Information Management and Systems, The Ohio State University, Columbus, Ohio
| | | | - Mia Hashibe
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,Department of Family and Preventive Medicine, University of Utah, Salt Lake City, Utah
| | - Anne C Kirchhoff
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,Department of Pediatrics, University of Utah, Salt Lake City, Utah
| | | | - Dan Bolton
- Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
| | - Carol Sweeney
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah.,Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.,Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| |
Collapse
|
44
|
Garvin JH, Herget KA, Hashibe M, Kirchhoff AC, Hawley CW, Bolton D, Sweeney C. Linkage between Utah All Payers Claims Database and Central Cancer Registry. Health Serv Res 2019. [PMID: 30675913 DOI: 10.1111/1475‐6773.13114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE To evaluate the linkage of claims from the Utah All Payers Claims Database (APCD) and Utah Cancer Registry (UCR). DATA SOURCES Secondary data from 2013 and 2014 Utah APCD and 2013 UCR cases. STUDY DESIGN This is a descriptive analysis of the quality of linkage between APCD claims data and cancer registry cases. DATA COLLECTION/EXTRACTION METHODS We used the LinkPlus software to link Utah APCD and UCR data. PRINCIPAL FINDINGS We were able to link 82.4 percent (9441/11 453) of the UCR reportable cancer cases with APCD claims. Of those linked, 66 percent were perfect matches. CONCLUSIONS The quality of identifiers is high, evidence that claims data can potentially supplement cancer registry data for use in research.
Collapse
Affiliation(s)
- Jennifer Hornung Garvin
- Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah.,Utah Cancer Registry, University of Utah, Salt Lake City, Utah.,Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.,Health Information Management and Systems, The Ohio State University, Columbus, Ohio
| | | | - Mia Hashibe
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,Department of Family and Preventive Medicine, University of Utah, Salt Lake City, Utah
| | - Anne C Kirchhoff
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,Department of Pediatrics, University of Utah, Salt Lake City, Utah
| | | | - Dan Bolton
- Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
| | - Carol Sweeney
- Utah Cancer Registry, University of Utah, Salt Lake City, Utah.,Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.,Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| |
Collapse
|
45
|
Lundell-Creagh R, Cowan C, Cowan P, Sweeney C, Zedeck S. RETIREMENT TRANSITIONS AMONG EMERITI AND THEIR PARTNERS: IMPLICATIONS FOR PROGRAM DEVELOPMENT. Innov Aging 2018. [DOI: 10.1093/geroni/igy031.3679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - C Cowan
- University of California, Berkeley, Psychology Department
| | - P Cowan
- University of California, Berkeley, Psychology Department
| | | | - S Zedeck
- University of California, Berkeley, Psychology Department
| |
Collapse
|
46
|
Gulbahce HE, Bernard PS, Weltzien EK, Factor RE, Kushi LH, Caan BJ, Sweeney C. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis. Cancer 2018; 124:4676-4684. [PMID: 30311638 DOI: 10.1002/cncr.31776] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 07/20/2018] [Accepted: 08/27/2018] [Indexed: 01/09/2023]
Abstract
BACKGROUND Although the proportion of triple-negative breast cancers (TNBCs) diagnosed among older women is low, the number of TNBC cases is substantial because of the high incidence of breast cancer after the age of 65 years. The molecular features of TNBC in this age group have not been well described. METHODS This study examined a population-based cohort of women with stage I to III TNBC diagnosed between the ages of 25 and 91 years with the PAM50 gene expression subtyping assay. The concordance between the TNBC classification by immunohistochemistry and the gene expression classification by PAM50, the expression of individual genes, and 5-year recurrence and breast cancer mortality in older women (≥65 years old) and younger women (<50 years old) was assessed. RESULTS The molecular subtype distribution in TNBC was significantly different according to the age at diagnosis. TNBC was more likely to be classified as basal-like in women younger than 50 years (sensitivity, 0.91; 95% confidence interval, 0.77-0.97) than women 65 years old or older (sensitivity, 0.72; 95% confidence interval, 0.48-0.87); 35% of clinical TNBC cases in the latter group were the human epidermal growth factor receptor 2 (HER2)-enriched subtype by molecular classification. Older women with TNBC also had significantly higher expression of ERBB2 and lower expression of all 10 proliferation-associated genes tested (P < .01). The risk of breast cancer death within 5 years was significantly higher in women with TNBC in comparison with women with hormone receptor-positive cancers in all age groups. CONCLUSIONS This study revealed differences in molecular subtypes among clinical TNBC cases based on patient age. A potentially targetable HER2-enriched group raises the possible need for intrinsic subtyping in older women with TNBC.
Collapse
Affiliation(s)
- H Evin Gulbahce
- Department of Pathology, University of Utah, Salt Lake City, Utah
| | - Philip S Bernard
- Department of Pathology, University of Utah, Salt Lake City, Utah
| | - Erin K Weltzien
- Division of Research, Kaiser Permanente Northern California, Oakland, California
| | - Rachel E Factor
- Department of Pathology, University of Utah, Salt Lake City, Utah
| | - Lawrence H Kushi
- Division of Research, Kaiser Permanente Northern California, Oakland, California
| | - Bette J Caan
- Division of Research, Kaiser Permanente Northern California, Oakland, California
| | - Carol Sweeney
- Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
| |
Collapse
|
47
|
tripathi A, Supko J, Gray K, Melnick Z, Taplin ME, Choudhury A, Pomerantz M, Bellmunt J, Yu C, Sun Z, Srinivas S, Kantoff P, Sweeney C, Harshman L. Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Morgans A, Chen YH, Jerrard D, Carducci M, Dipaola R, Wagner L, Cella D, Sweeney C. Association between patient reported quality of life (QOL) and survival: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Sussman G, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, Grattan C, Hollis K, Hunter S, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Maurer M, Nakonechna A, Ortiz de Frutos J, Reynolds M, Sweeney C, Tian H, Weller K, Wolin D, Balp MM. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU. Allergy 2018; 73:1724-1734. [PMID: 29460968 PMCID: PMC6055840 DOI: 10.1111/all.13430] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/05/2018] [Indexed: 12/13/2022]
Abstract
Background ASSURE‐CSU revealed differences in physician and patient reporting of angioedema. This post hoc analysis was conducted to evaluate the actual rate of angioedema in the study population and explore differences between patients with and without angioedema. Methods This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria (CSU). Physicians abstracted angioedema data from medical records, which were compared with patient‐reported data. Patients in the Yes‐angioedema category had angioedema reported in the medical record and a patient‐reported source. For those in the No‐angioedema category, angioedema was reported in neither the medical record nor a patient‐reported source. Those in the Misaligned category had angioedema reported in only one source. Statistical comparisons between Yes‐angioedema and No‐angioedema categories were conducted for measures of CSU activity, health‐related quality of life (HRQoL), productivity and healthcare resource utilization (HCRU). Regression analyses explored the relationship between Dermatology Life Quality Index (DLQI) score and angioedema, adjusting for important covariates. Results Among evaluable patients, 259 (40.3%), 173 (26.9%) and 211 (32.8%) were in the Yes‐angioedema, No‐angioedema and Misaligned category, respectively. CSU activity and impact on HRQoL, productivity, and HCRU was greater for Yes‐angioedema patients than No‐angioedema patients. After covariate adjustment, mean DLQI score was significantly higher (indicating worse HRQoL) for patients with angioedema versus no angioedema (9.88 vs 7.27, P < .001). The Misaligned category had similar results with Yes‐angioedema on all outcomes. Conclusions Angioedema in CSU seems to be under‐reported but has significant negative impacts on HRQoL, daily activities, HCRU and work compared with no angioedema.
Collapse
Affiliation(s)
- G. Sussman
- University of Toronto; Toronto ON Canada
| | | | - F. Bérard
- Claude Bernard University Lyon; Villeurbanne France
| | - W. Canonica
- IRCCS-Humanitas Research Hospital; Humanitas University; Rozzano-Milano Italy
| | - H. Oude Elberink
- Department of Allergology; University of Groningen; University Medical Center Groningen; Groningen The Netherlands
- GRIAC Research Institute; University of Groningen; University Medical Center Groningen; Groningen The Netherlands
| | | | | | - K. Hollis
- RTI Health Solutions; Research Triangle Park NC USA
| | - S. Hunter
- RTI Health Solutions; Research Triangle Park NC USA
| | - A. Knulst
- University Medical Center; Utrecht The Netherlands
| | | | - C. Lynde
- Lynderm Research; Toronto ON Canada
| | - A. Marsland
- Salford Royal Hospital; University of Manchester; Salford UK
| | | | - M. Maurer
- Charité - Universitätsmedizin Berlin; Berlin Germany
| | - A. Nakonechna
- Royal Liverpool and Broadgreen University Hospitals; Liverpool UK
| | | | - M. Reynolds
- RTI Health Solutions; Research Triangle Park NC USA
| | - C. Sweeney
- RTI Health Solutions; Research Triangle Park NC USA
| | - H. Tian
- Novartis Pharmaceuticals Corporation; East Hanover NJ USA
| | - K. Weller
- Charité - Universitätsmedizin Berlin; Berlin Germany
| | - D. Wolin
- RTI Health Solutions; Research Triangle Park NC USA
| | | |
Collapse
|
50
|
Madsen MJ, Knight S, Sweeney C, Factor R, Salama M, Stijleman IJ, Rajamanickam V, Welm BE, Arunachalam S, Jones B, Rachamadugu R, Rowe K, Cessna MH, Thomas A, Kushi LH, Caan BJ, Bernard PS, Camp NJ. Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15. Cancer Epidemiol Biomarkers Prev 2018; 27:644-652. [PMID: 29650789 DOI: 10.1158/1055-9965.epi-17-0887] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Revised: 11/30/2017] [Accepted: 04/02/2018] [Indexed: 11/16/2022] Open
Abstract
Background: Breast tumor subtyping has failed to provide impact in susceptibility genetics. The PAM50 assay categorizes breast tumors into: Luminal A, Luminal B, HER2-enriched and Basal-like. However, tumors are often more complex than simple categorization can describe. The identification of heritable tumor characteristics has potential to decrease heterogeneity and increase power for gene finding.Methods: We used 911 sporadic breast tumors with PAM50 expression data to derive tumor dimensions using principal components (PC). Dimensions in 238 tumors from high-risk pedigrees were compared with the sporadic tumors. Proof-of-concept gene mapping, informed by tumor dimension, was performed using Shared Genomic Segment (SGS) analysis.Results: Five dimensions (PC1-5) explained the majority of the PAM50 expression variance: three captured intrinsic subtype, two were novel (PC3, PC5). All five replicated in 745 TCGA tumors. Both novel dimensions were significantly enriched in the high-risk pedigrees (intrinsic subtypes were not). SGS gene-mapping in a pedigree identified a 0.5 Mb genome-wide significant region at 12q15 This region segregated through 32 meioses to 8 breast cancer cases with extreme PC3 tumors (P = 2.6 × 10-8).Conclusions: PC analysis of PAM50 gene expression revealed multiple independent, quantitative measures of tumor diversity. These tumor dimensions show evidence for heritability and potential as powerful traits for gene mapping.Impact: Our study suggests a new approach to describe tumor expression diversity, provides new avenues for germline studies, and proposes a new breast cancer locus. Similar reparameterization of expression patterns may inform other studies attempting to model the effects of tumor heterogeneity. Cancer Epidemiol Biomarkers Prev; 27(6); 644-52. ©2018 AACR.
Collapse
Affiliation(s)
- Michael J Madsen
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Stacey Knight
- School of Medicine, University of Utah, Salt Lake City, Utah.,Intermountain Healthcare, Salt Lake City, Utah
| | - Carol Sweeney
- School of Medicine, University of Utah, Salt Lake City, Utah
| | - Rachel Factor
- School of Medicine, University of Utah, Salt Lake City, Utah
| | - Mohamed Salama
- School of Medicine, University of Utah, Salt Lake City, Utah
| | - Inge J Stijleman
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | | | - Bryan E Welm
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,School of Medicine, University of Utah, Salt Lake City, Utah
| | - Sasi Arunachalam
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Brandt Jones
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | | | - Kerry Rowe
- Intermountain Healthcare, Salt Lake City, Utah
| | | | - Alun Thomas
- School of Medicine, University of Utah, Salt Lake City, Utah
| | | | - Bette J Caan
- Division of Research, Kaiser Permanente, Oakland, California
| | - Philip S Bernard
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.,School of Medicine, University of Utah, Salt Lake City, Utah
| | - Nicola J Camp
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. .,School of Medicine, University of Utah, Salt Lake City, Utah
| |
Collapse
|